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Toll-like receptor 4 (TLR4) is an important vertebrate innate immune receptor. 
TLR4 recognizes both endogenous and exogenous danger signals to trigger an NF-kB 
dependent inflammatory response. While exogenous danger signal recognition is an 
essential part of pathogen response by the innate immune system, endogenous danger 
signal recognition by TLR4 can lead to chronic and pathological inflammation. 
Understanding the differences in recognition of these two types of danger signals would 
allow for independent modulation of pathogen and host triggered inflammatory response 
through TLR4. Here, we examine the evolution of activation of TLR4 by two agonists, 
pathogen-derived lipopolysaccharide and host-produced S100A9. We show that these 
two types of signals evolved earlier than previously thought. We identified TLR4 
cofactors MD-2 and CD14 in amphibians and fish, and validated that zebrafish TLR4 can 
recognize LPS. By contrast, we find that S100A9 activation evolved in the ancestor of 
amniotes. We identified an ortholog of S100A9 in birds and reptiles capable of activating 
TLR4. Using comparative immunology, we found that the requirements for LPS and 
S100A9 activation are different. In addition to our evolutionary studies, we used 
molecular approaches to probe if zinc binding to S100A9 is necessary for TLR4 




zinc. Finally, we describe how our evolutionary approach led to mechanistic hypotheses 
regarding TLR4 activation by both LPS and S100A9. This has led to ongoing projects in 
the Harms lab. This dissertation includes previously published and unpublished co-
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HISTORICAL AND FUNCTIONAL INSIGHTS INTO TOLL-LIKE RECEPTOR 4 
ACTIVATION BY LIPOPOLYSACCHARIDE AND CALGRANULINS 
 
This chapter contains co-authored material. Portions of this chapter were published as 
Loes, A.N., J.T. Bridgham, M.J. Harms. 2018. “Coevolution of the Toll-like receptor 4 
complex with calgranulins and lipopolysaccharide”. Front. Immunol. 9:304. This chapter 
was written by me, with editorial assistance from M.J. Harms 
 
Toll-like Receptors, an Important Line of Defense for the Innate Immune System 
The immune system must recognize when a pathogen is present. Cell surface 
receptors, known as pattern recognition receptors serve as the first line of defense for the 
innate immune system. These receptors recognize conserved molecules from pathogens1. 
The ability to recognize these pathogenic signals and rapidly respond is an essential part 
of protecting the host from infection.  
 The Toll-like receptor (TLR) family is a well-studied class of pattern recognition 
receptors2. In 1991, the first Toll was discovered in Drosophila3. The TLR family 
expanded across vertebrates. To date, 13 TLRs have been identified in mammals4,5. 
The diversity of TLRs found across the mammals allows for recognition of 
diverse types of ligands, known as pathogen-associated molecular patterns (PAMPs)6. 




biological molecules including nucleic acids, proteins, and small molecules via similarly 
structured but significantly diverged, leucine-rich repeats (LRRs)4,6–9.  
While the ectodomains of TLRs have diversified over time to specifically 
recognize certain types of molecules, the internal domains and downstream signaling 
cascades have been conserved across mammalian Tolls5,10. The internal domain of TLRs, 
known as the Toll-interleukin (IL)-1 receptor (TIR) domain is highly conserved across 
vertebrates5,10. TIR domains recognize adaptor molecules including Myd88 and TRIF 
which trigger highly conserved downstream signaling cascades leading to activation of 
the transcription factor NF-kB11. NF-kB activation triggers expression of inflammatory 
cytokines3. This functions as an alarm signal, recruiting neutrophils to the site of 
infection and stimulating an inflammatory response to control the spread of infection.  
 
Lipopolysaccharide Recognition by Toll-like Receptor 4 and Septic Shock 
One of the first identified mammalian Toll-like receptors and the most well-
studied is Toll-like receptor 4 (TLR4). TLR4 recognizes lipopolysaccharide (LPS), a 
component of the cell wall of Gram-negative bacteria. Through LPS-recognition, TLR4 
provides a highly sensitive and tuned alarm for presence of bacteria in the bloodstream. 
This early response from TLR4 amplifies the signal of bacterial presence in hosts and is 
essential for control of infection. 
The inflammatory response triggered by LPS through TLR4 is a critical gateway 
for initiation of septic shock12–14. Sepsis is a common cause of death in hospitals in the 
United States. The high mortality rate associated with sepsis is due to the intense 




Development of antagonists of TLR4 activation by LPS, or inhibitors of downstream 
response elements has been a clinical goal for many years15–18. 
Binding and activation of TLR4 by LPS is relatively well understood at the 
molecular level. Like many other TLRs, activation of TLR4 requires homodimerization 
following ligand binding19. TLR4 activation by LPS requires two cofactors MD-2 and 
CD1420–28. MD-2 functions like a hydrophobic pocket for LPS molecules(Fig. 1.1)17,29–32. 
MD-2 interacts with TLR4 monomers, even in the absence of ligand21. LPS binding by 
MD-2 induces a conformational change and allows for formation dimer with an 
additional TLR4/MD-2 molecule19,31. MD-2 comprises a significant portion of the 
dimerization interface and is essential for LPS binding and activation of TLR417,23,32. LPS 
is often found in the extracellular space as LPS-aggregates33,34. In order for independent 
LPS molecules to bind to TLR4/MD-2, these aggregates need to be broken up by LPS-
binding protein (LBP)35,36. CD14 works in concert with LBP to deliver LPS molecules to 
the TLR4/MD-2 complex35,37. CD14 plays an important role in LPS concentration for a 
more sensitive response to LPS by TLR432,38,39.  
 
Endogenous Molecule Recognition by TLR4 and Chronic Inflammation 
 In addition to its role in septic shock, Toll-like receptor 4 also plays a role in 
sterile inflammation13,18,40. Stressed or damaged tissues release a variety of endogenous 
molecules, known as damage-associated molecular patterns (DAMPS), which trigger the 
activation of inflammatory pathways9,41. Many of these molecules have been shown to be 
recognized by TLRs, indicating a dual role for these receptors in pathogen-mediated and 




 TLR4 has been shown to recognize a large diversity of endogenous ligands – 
proteins, lipoproteins, lipids43–47. In contrast to the LPS response, endogenous activation 
of TLR4 is not well-characterized at the molecular level. However, endogenous 
activation of TLR4 plays a role in many inflammatory diseases including 
atherosclerosis48,49, liver disease50,51, kidney disease52, pulmonary disease53,54, and 
inflammatory bowel disease (IBD)55–60.  
S100A9 can act as a DAMP, activating a potent pro-inflammatory response 
through a direct interaction with TLR461–63. S100A9 is present in hosts as both a highly 
pro-inflammatory homodimer and as a part of the antimicrobial heterocomplex 
calprotectin (CP)61,64,65. During IBD, CP is found at high levels in the gut and is directly 
correlated with the degree of inflammation66. Expression of S100A9 is driven by LPS, 
and functions as an amplification of pathogen signaling through TLR464.  
Understanding sterile inflammation and endogenous activation of TLR4 is 
important, not only for tempering inflammation in chronic diseases but also in treating 
septic shock. As sterile inflammation and LPS-driven inflammation are not fully separate, 
disruption of the chronic signal can be therapeutically effective in disrupting the positive 
feedback loop of endogenous molecule driven inflammation. Deletion of S100A9, for 
example, has been shown to have a protective effect for septic shock67. Therefore, 
S100A9 has been identified as a potential therapeutic target to control chronic 
inflammation68. Further work examining how endogenous and exogenous activation of 
TLR4 differ mechanistically may lead to therapeutic strategies for controlling chronic 




The molecular mechanism for endogenous activation of TLR4 by S100A9 is not 
known. Identifying how S100A9 activation differs from LPS activation of TLR4 is 
critical to the establishment of therapeutic strategies for disrupting this powerful pro-
inflammatory signal. Further, establishing when these two types of signaling regimes 
evolved for TLR4 is critical to identifying appropriate model organisms for studying the 
importance of these types of signaling in human disease.  
 
Figure 1.1. Toll-like receptor 4 activation by exogenous and endogenous danger 
signals Structure of TLR4 (turquoise) with co-factors MD-2 (navy) and CD14 (lilac) 
can be activated by LPS (pink) and S100A9 (violet).69–71 
 
The primary aim of this work is to better understand the differences between 
endogenous activation of TLR4 by S100s and exogenous activation by LPS (Fig. 1.1). I 
use a combination of biochemical and evolutionary approaches to gain historical and 
functional insight into these two types of pro-inflammatory signals. With evolutionary 
biochemistry, we were able to discern differences across extant species and illuminate the 





Molecular Evolution as a Powerful Lens for Biochemistry 
A primary goal of biochemistry is understanding the physical basis for the 
function of biological molecules. Traditional biochemical methods primarily employ 
targeted analyses towards the identification of mutations which disrupt the function of 
interest72,73. A key drawback to this approach is that there are many types of perturbations 
that can disrupt a function but are not mechanistically informative. For complex 
molecular traits, it is often challenging to puzzle out the molecular and physical basis for 
a function from a non-functional mutant74.  
A complementary approach is to place the interaction in the context of its 
evolutionary history. Evolutionary biochemistry combines history and molecular 
mechanisms to reveal not only how proteins work, but also the process by which they 
came to work that way75. Two powerful tools for dissecting the evolution of protein 
function are phylogenetics and ancestral state reconstruction76–80. These approaches allow 
one to ask how changes in amino acid sequence, over the course of evolution, led to a 
change in protein function. This offers a distinct advantage over traditional mutagenesis 
approaches; rather than assessing how to break a function of interest, evolutionary 
approaches give one a blueprint to build an interesting function onto a historical protein 
framework81. These power and impact of these approaches will be discussed in more 
detail in the last chapter of this work. 
 
Advantages of an Evolutionary Approach in Immunology  
Evolutionary biochemistry has powerful advantages in studies of immune 




in alternate organisms are not always directly applicable to human disease82. These 
challenges are most pronounced in infectious disease research, where the host-pathogen 
arms race has led to coevolution with host immune systems which result in differences 
even across relatively short evolutionary timescales.  
Mice are a favored model organism for understanding human health. Mice and 
humans shared a common ancestor approximately 90 million years ago. This shared 
evolutionary history accounts for a great deal of the similarity in immune systems. 
However, many changes have occurred along the respective primate and rodent lineage 
since the common ancestor which results in a variety of differences, leading to difficulties 
in the ability to translate results in mice to human systems. It is essential, therefore that 
evolutionary history is considered when utilizing animal models. This allows one to 
separate the changes that have occurred along specific lineages from the core molecular 
basis for immune protein function.  
An additional advantage of evolutionary biochemistry approaches for 
immunology stems from the relatively rapid evolution that has occurred within this 
system. Homology is often used to assign functions across related organisms. However, 
particularly within rapidly evolving systems, conservation in function at the macroscopic 
level is not always indicative of conservation in mechanism at the molecular level83. 
Organisms may contain the same protein performing the same function but given 
differences in the molecular basis of interactions, which arises from coevolution between 
complex components, identification of a disruptive mutation in one organism may have 
limited if any effect in another. This can be particularly challenging for drug 




alert one to lineage-specific coevolution and therefore potential challenges in 
translational studies.  
Development of inhibitors of TLR4 has been hampered in part by differential 
response to potential inhibitory molecules between humans and preclinical animal 
models84. Several molecules function as antagonists in humans but agonists in mice85–87. 
Further, drugs have been developed to work in murine models that have been found not 
to function similarly in humans88,89. Given the significant cost of development of 
therapeutics and clinical testing in animal models and human subjects, a better 
understanding of the differences and similarities between human and animal models 
could provide a framework to begin development of potent and more broadly functional 
inhibitors of this pathway.  
 
Evolutionary Biochemistry for Understanding TLR4 Activation by LPS and 
Calgranulins 
 Here, I describe the application of a combination of evolutionary and biochemical 
techniques to contribute to the understanding of LPS and calgranulin activation of TLR4. 
To take apart the evolution of TLR4 activation by both endogenous and exogenous 
ligands, my colleagues and I determined the species distribution of TLR4 activation by 
LPS and calgranulins. These studies contributed to the overall goal of isolating the 
evolutionary intervals in which these functions evolved. Next, we used a direct 
biochemical approach to understand the role for zinc in the interaction between S100A9 
and TLR4. This work further contributes to our understanding of the molecular 




state reconstruction for calgranulins, TLR4, MD-2 and CD14 to generate hypothesis 
regarding the biochemical basis for functions exhibited by these proteins in extant 
species. These studies together demonstrate the power of combining an understanding of 
evolutionary history with biochemical analysis to break apart molecular mechanisms for 
interesting protein functions.  
Chapter II describes our work investigating when LPS activation of TLR4 
evolved. LPS recognition by TLR4 across the amniotes has been shown to be dependent 
on the presence of cofactors MD-2 and CD1490–92. The lack of identification of these 
cofactors in amphibians and fish has led some to conclude that LPS activation of TLR4 
does not occur in fish93,94. However, we identified a putative zebrafish MD-2. 
Phylogenetic analysis and synteny support classification of this gene as an MD-2. Using a 
cell culture assay we show that expression of this protein with zebrafish TLR4a allows 
zebrafish TLR4 to activate an NF-kB cascade in response to LPS. By reporting the 
identification of MD-2 and CD14 in amphibians and fish, we show that this function of 
TLR4 evolved much earlier than previously thought. This also implies that fish may be a 
good model organism for understanding septic shock. 
Chapter III examines when S100 activation of TLR4 evolved. TLR4 induces 
inflammation in response to both pathogen- and host-derived molecules. 
Lipopolysaccharide (LPS) recognition by TLR4 has been shown to occur across 
vertebrates, but endogenous signaling through TLR4 has not been validated outside of 
placental mammals. To determine whether endogenous danger signaling is shared across 
amniotes, we studied the evolution of TLR4-activation by the calgranulin proteins 




in placental mammals. We performed phylogenetic and syntenic analysis and found 
MRP-126 — a gene in birds and reptiles — is likely orthologous to the mammalian 
calgranulins. We then used an ex vivo TLR4 activation assay to establish that calgranulin 
pro-inflammatory activity is not specific to placental mammals but is also exhibited by 
representative marsupial and sauropsid species. This activity is strongly dependent on the 
cofactors CD14 and MD2 for all species studied, suggesting a conserved mode of 
activation across the amniotes. Ortholog complementation experiments between the 
calgranulins, TLR4, CD14, and MD2 revealed extensive lineage specific-coevolution and 
multi-way interactions between components that are necessary for the activation of NF-
κB signaling by calgranulins and LPS. Our work demonstrates that calgranulin activation 
of TLR4 evolved at least ~320 million years ago and has been conserved in the amniote 
innate immune system. 
Chapter IV examines how S100A9 activates TLR4. S100A9 promotes a pro-
inflammatory response through a direct interaction with Toll-like receptor 4 (TLR4). 
While the mechanism for LPS recognition by TLR4 is relatively well understood, the 
molecular requirements and mechanism for activation by S100 proteins is not known. 
The interaction between S100A9 and TLR4 has previously been shown to be regulated 
by zinc68. We find that the tail, which is predicted to undergo significant structural 
rearrangement upon zinc binding, is not directly involved in the interaction of S100A9 
with TLR4. We further demonstrate that S100A9 is prone to reversible, zinc-dependent 
aggregation and show that this aggregation is dependent on the presence of metal binding 




transition metal binding site is not necessary for the interaction with TLR4 and that 
activation of TLR4 by S100A9 occurs even in the absence of metal binding. 
Finally, Chapter V demonstrates the power of utilizing phylogenetics and 
ancestral state reconstruction to gain insight into protein function. Phylogenetics on 
TLR4, MD-2, CD14, and the calgranulin proteins reveal some of the many different types 
of hypotheses evolutionary strategies generate. We show that by using ancestral state 
reconstruction we were able to polarize when a transition occurred in S100 proteins 
which led to proteolytic susceptibility. We also show how consideration for distribution 
of a function extant species can lead to identification of the historical substitutions which 
were important for the evolution of given functions. In addition, we show that co-
evolutionary analysis can lead to identification of the core conserved molecular 
requirements for a function of interest and lead to hypotheses regarding how coevolution 
of complex components can lead to incompatibility between extant molecules. Finally, 
we show that phylogenetics can lead to identifications of the hierarchy of functions for a 
multi-functional molecule. These studies, while in preliminary stages, strongly 
demonstrate how an evolutionary perspective can lead to molecular level hypotheses that 






LIPOPOLYSACCHARIDE ACTIVATES ZEBRAFISH TOLL-LIKE RECEPTOR 4 
 
Portions of this chapter are co-authored. Experiments described here were conducted by 
me. This excerpt was written by me in collaboration with M.J. Harms.  
 
INTRODUCTION 
The zebrafish (Danio rerio) is a powerful model organism for studies of 
vertebrate innate immunity95. It has mature genetic resources, rapid generation time, a 
clear embryo, and facile germ-free derivation96,97. This makes it extremely useful as a 
complement to other model organisms for mechanistic studies of innate immune function.  
A major difficulty for relating zebrafish and mammalian innate immunity is an 
apparent difference in how they respond to lipopolysaccharide (LPS). LPS is a 
component of the cell wall of Gram-negative bacteria that, in amniotes, plays a critical 
role in initiating inflammation in response to infection. LPS is the primary driver of 
septic shock and plays roles in Crohn’s disease, inflammatory bowel disease, and other 
inflammatory disorders49,51,54,56,57,98. Across amniotes, LPS activates NF-kB signaling via 
Toll-like receptor 4 (TLR4)90,91. Peripheral proteins, including lipid binding protein 
(LBP) and cluster of differentiation 14 (CD14) bring LPS to TLR438,99,100. They then load 
LPS into the essential cofactor MD-2 (also known as LY96), which forms a tight 
complex with TLR421. Binding of LPS triggers dimerization of TLR4 and activation of 




Despite the central role of TLR4/MD-2 in LPS recognition in amniotes, it is 
currently believed that zebrafish do not respond to LPS via TLR493,94. This makes it 
difficult to relate studies of inflammation in zebrafish back to mammals. It is also rather 
puzzling. Zebrafish possess three TLR4 genes (tlr4ba, tlr4a1, and tlr4bb), at least one of 
which is widely expressed (tlr4ba)10. Further, the downstream responses to LPS are 
similar between mammals and zebrafish. Like in amniotes, LPS activates NF-kB via a 
Myd88-dependent pathway in zebrafish102,103. Likewise, the expression patterns of genes 
induced by LPS stimulation are highly similar between mouse and zebrafish104. Why 
would the downstream LPS response in zebrafish be consonant with the LPS response in 
mammals if they use entirely different initial receptors? 
 
Figure 2.1. Mammalian TLR4 activation involves cofactors MD-2 and CD14. A. 
Schematic representation of LPS transfer from CD14 to TLR4-MD-2 complex. B. 





We set out to reevaluate the claim that zebrafish do not use TLR4 for LPS 
recognition. The current view is based on three lines of evidence. The most critical is the 
apparent lack of MD-2 in zebrafish and other bony fishes93,94,105. In amniotes, MD-2 is an 
essential TLR4 co-factor, as it forms the binding site at which LPS binds (Fig. 2.1B)21. 
Although zebrafish possess three different TLR4 genes, without MD-2 these cannot 
respond to LPS in the same manner as amniote TLR493,94. The second line of evidence is 
that zebrafish TLR4s do not activate NF-kB in response to LPS in ex vivo assays, even 
when complemented with a mouse or human MD-293,94. This has been interpreted as 
indicating that these receptors would not be able to respond to LPS, even if MD-2 was 
present.  
Finally, it has been argued that the zebrafish “TLR4” genes are paralogs rather 
than orthologs to amniote TLR494. In this evolutionary scenario, an ancestral Toll-like 
receptor gene duplicated, allowing subfunctionalization and/or neofunctionalization of 
each duplicate gene. After this event, tetrapods and bony fishes diverged.  Finally, 
tetrapods lost one gene and retained the gene we now call TLR4; bony fishes, in contrast, 
lost TLR4 and retained the other gene. In this scenario, we would expect the “TLR4” 
proteins from bony fishes to behave differently than TLR4 from tetrapods, as the two 
genes had an opportunity to functionally diverge prior to the speciation of tetrapods and 
bony fishes.  
We set out to carefully evaluate each of these lines of evidence using resources 
unavailable when the initial investigations of zebrafish TLR4 were performed. Using 
careful bioinformatics, we found an ortholog to mammalian MD-2 in multiple bony fish 




signaling in response to LPS. Finally, we re-examine the evolutionary history of TLR4 in 
zebrafish. Both model-based phylogenetics and the genomic location of TLR4 in the gar 
(Lepisosteus oculatus) genome support assigning the TLR4 genes as co-orthologs of 
tetrapod TLR4.  
Our results suggest that zebrafish TLR4 responds to LPS in the same manner as 
tetrapod TLR4s. This means that the LPS-induced activation of the TLR4/MD-2 complex 
evolved 110 million years earlier than previously appreciated. Further, this implies that 
studies of LPS-induced inflammation in zebrafish can be directly mapped to mammals.  
 
RESULTS 
Identification of an MD-2 like protein in amphibians and fishes 
 Our first question was whether we could find MD-2 in bony fishes. We used the 
human MD-2 protein sequence to BLAST against the zebrafish genome and 
transcriptomes. This returned no significant hits. We, therefore, took a more 
phylogenetically informed strategy.  
 Relative to humans, the earliest branching functionally characterized TLR4/MD-2 
complex is in chickens. We, therefore “walked out” from amniotes towards fishes. We 
started with amphibians. We BLASTed human MD-2 against the Xenopus laevis genome. 
This revealed a hit to a hypothetical protein with 30% identity (OCT74818.1). When 
reverse-BLASTed against the human proteome, this hit returns MD-2. To validate the 
sequence, we compared it to a collection of functionally characterized MD-2 proteins 
from amniotes. We found that the X. laevis gene appeared to be N-terminally truncated.  




By BLASTing against available amphibian transcriptomes106–109, we further identified 
putative MD-2 proteins in Rhinella marina, and Odorrana margaretae (Fig. AA1). 
 With these putative amphibian MD-2 sequences in hand, we returned to our 
search for a zebrafish MD-2. A BLAST against a zebrafish transcriptome using the X. 
laevis sequence revealed a likely transcript (23% identity). We then searched additional 
fish transcriptomes available from the Fish1TK project and identified a set of transcripts 
from three species that matched MD-2 (Fig. AA1). The putative MD-2 genes we 
identified in bony fishes were highly diverged. On average, they exhibited only 26% 
identity against human MD-2, and only ~40% identity relative to one another.  
We next set out to assign the orthology of these putative MD-2 sequences. Our 
primary concern was that these newly identified sequences were paralogs of MD-2—
likely the closely related protein, MD-1. We, therefore, built a phylogenetic tree to 
elucidate whether these newly identified sequences grouped with MD-1 or MD-2. We 
constructed an alignment of 294 MD-1 and MD-2 protein sequences sampled from 
amniotes, amphibians, and fishes and then used this to infer a maximum likelihood 
phylogeny (Fig. 2.2A).  
The putative amphibian and bony fish MD-2 sequences grouped with the tetrapod 
MD-2 sequences with strong support (SH = 0.99). The MD-1/MD-2 protein tree largely 
reproduced the species tree, with the exception of amphibians. On the MD-1 lineage, 
amphibians form a polytomy with fishes at the base of the tree; on the MD-2 lineage, 
they are placed inside the amniote clade with a relatively short internal branch. This is 
likely an artifact of the small number of amphibian sequences available, as well as the 





Figure 2.2. Phylogeny and synteny for identified protein in zebrafish support 
classification as an MD-2 A) Maximum likelihood phylogeny of MD-2 and MD-1 
proteins. Wedges are collapsed clades of orthologs, with wedge height corresponding 
to the number of included taxa and wedge length indicating the longest branch length 
with the clade. Support values are SH-supports calculated using an approximate 
likelihood ratio test. Clades are colored to highlight MD-2 and MD-1 classification. 
The taxa included in each clade are noted on the tree by silhouettes of mammals 
(mouse), sauropsids (chicken), amphibians (frog), and fish (zebrafish). B) Genomic 
organization of genes surrounding MD-2 in vertebrates. Arrows for genes represent the 
coding strand. Approximate distances between genes are represented by the length of 





Overall, the tree is consistent with a single gene duplication event sometime 
before the evolution of bony vertebrates. MD-1 and MD-2 were then preserved along 
most descendant lineages. This said, the protein sequences of MD-1 and, particularly, 
MD-2 are evolving rapidly. The total branch lengths between the last common ancestor 
of MD-2 to its human and zebrafish descendants are 2 and 2.44, respectively. Put another 
way, on each lineage, each position in the MD-2 sequence has changed its amino acid ~2-
2.5 times over the last 430 million years. Only 7 of ~160 positions are in MD-2 are 
universally conserved across the clade.  
To cross-validate the orthology of our newly identified md2 genes, we next 
examined their location in the X. laevis and D. rerio genomes. We found that the synteny 
is consistent with md2s from other vertebrates (Fig. 2.2B). In five genomes sampled from 
across bony vertebrates—including X. laevis and D rerio—md2 is located between 
tmem70 and jph1b (Table AA1). This provides strong evidence that the amphibian and 
fish MD-2 genes are, in fact, orthologous to amniote MD-2.  
Due to the genome duplication event that occurred along the zebrafish lineage, we 
also looked for a second copy of md2. We examined the genomic location of the jph1a 
paralog, but we were unable to identify an additional gene with any similarity to md2. It 
appears that an inversion may have occurred in this region, complicating identification by 
synteny alone. This said, no additional transcripts were identified within the zebrafish 
transcriptome with similarity to the identified zebrafish md2 sequence. This is consistent 






Zebrafish TLR4a/MD-2 can activate NF-kB in response to lipopolysaccharide 
 Our phylogenetic and syntenic analysis are consistent with zebrafish MD-2 gene 
being homologous to amniote MD-2; however, this does not demonstrate that the protein 
is playing the same role played by amniote MD-2. Particularly given the low similarity 
between zebrafish MD-2 and its amniote orthologs, it was not clear that the zebrafish 
MD-2 would be capable of mediating the TLR4 response to MD-2. We, therefore, turned 
to an ex vivo cell culture assay to assess the ability of the zebrafish MD-2 to partner with 
zebrafish TLR4a and TLR4b for LPS activation. In this assay, we use luciferase to 
quantify NF-kB output in response to exogenously applied LPS.  
Previous experiments found that neither TLR4a nor TLR4b activated in response 
to LPS when complemented with either human or mouse MD-2. One key difference 
between our experiments and those done previously is the sequence of TLR4a used. 
Previous investigators used a construct that was ~75 amino acids shorter than tetrapod 
TLR4s. This construct is missing both the signal peptide required to target TLR4 to the 
cell surface and a region of the protein that is likely critical for MD-2 binding (Fig. AA2). 
In contrast, we used a full-length ORF (XM_009307228.3).  We started by co-
transfecting cells with zebrafish MD-2 and zebrafish TLR4a or TLR4b and measuring 
NF-kB activation in response to exogenously applied LPS. We saw no activation (Fig. 
2.3).  
In these experiments, we are attempting to activate a TLR4/MD-2 complex 
without CD14—an important peripheral protein that brings LPS to TLR4/MD-2 
complexes in amniotes, dramatically increasing the NF-kB response. We thus co-




observed potent activation of NF-kB by the TLR4a/MD-2 complex (Fig. 2.3). To verify 
that this depended on MD-2, rather than CD14, we tested the activation of TLR4 and 
CD14 without MD-2—this complex did not respond to LPS (Fig. 2.3).  
 
Figure 2.3. LPS activates zebrafish TLR4a with zebrafish MD-2 and human 
CD14. Activation of zebrafish TLR4a (a) and TLR4b (b) with 400 ng/mL LPS in the 
presence and absence of zebrafish MD-2 and human CD14. Points are the technical 
replicates from three biological replicates. Bold lines are the mean of the biological 
replicates. Error bars are a standard error on the mean of the biological replicates. 
 
We also verified that the zebrafish TLR4a/MD-2 complex, complemented with 
human CD14, exhibited a dose-dependent response to LPS. This was the case (Fig. 
AA3). The concentrations of LPS needed for activation of the zebrafish TLR4/MD-2 
complex was much higher than those needed for activation of the human proteins in these 
cells. However, we saw activation patterns comparable to that observed for the turtle LPS 
in the human background with matched MD2 and CD1491.  
 
Amniote CD14 and MD-2 allow LPS-induced activation of zebrafish TLR4a  
 Our results strongly support the hypothesis that zebrafish TLR4a/MD-2 can 




supporting, mammalian protein (human CD14). To determine if this was an artifact of the 
human protein, we tested the LPS activation of TLR4a/MD-2 in the presence of human, 
mouse, opossum, and chicken CD14. We found that all but the chicken CD14 were able 
to support the activation of the complex (Fig. 2.4A). This suggests the activity induced by 
CD14 is a general property of CD14 proteins.  
Figure 2.4. Shared molecular mechanism for cofactors CD14 and MD-2s across 
vertebrates A) Cross-reactivity of amniote CD14s with the zebrafish TLR4a/MD-2 
complex, B) Cross-reactivity of amniote MD-2s with zebrafish TLR4a C) Conserved 
binding interface between MD-2 and N-terminus of TLR4 for vertebrates. Points are 
the technical replicates from three biological replicates. Bold lines are the mean of the 
biological replicates. Error bars are a standard error on the mean of the biological 
replicates. 
 
We also looked for evidence of a zebrafish CD14 gene; however, we were unable 
to locate such a gene. The closest paralog to CD14 in zebrafish is TLR2. We therefore 
co-transfected zebrafish TLR4a/MD-2 with TLR2. This complex, however, did not 
activate in response to LPS (Fig. AA4). The simplest explanation for this failed activation 
is that TLR2 cannot perform the same role as CD14; however, this could also reflect 




experiments were done in human cells), or a missing secondary cofactor (such as a fish 
LPS binding protein).  
 Finally, to see if zebrafish TLR4a was behaving similarly to amniote TLR4, we 
investigated whether MD-2 from other species to act in concert with zebrafish TLR4a. 
We co-transfected TLR4a in the presence of human, mouse, and opossum MD-2. We saw 
complementation by both mouse and opossum MD-2 for LPS activation of zebrafish 
TLR4a (Fig. 2.4B). This suggests that the requirements for activation by the TLR4/MD-2 
complex have been conserved across vertebrates.  
 
Zebrafish TLR4 genes are likely co-orthologous to tetrapod TLR4 
The evidence supporting paralogy from previous phylogenetic analyses was 
mixed: a gene-tree supported orthology, while a syntenic analysis supported paralogy. 
We, therefore, revisited the question of orthology using genomic tools that were not 
available when the first analysis was performed. 
As with our analysis of MD-2, we started with a phylogenetic tree and then turned 
to synteny. For the phylogenetic tree, we constructed a multiple sequence alignment 
containing 263 TLR4 sequences and 190 RP105 sequences (also known as CD180) as an 
outgroup. In the resulting maximum likelihood tree, TLR4 and RP105 form distinct, 
well-supported clades (Fig. 2.5A). Within the TLR4 clade, zebrafish TLR4a and TLR4b 
form a monophyletic group with other teleost fish TLR4s. The most straightforward 
interpretation of this result is TLR4a and TLR4b are co-orthologous to tetrapod TLR4s, 
and that the duplication of the tlr4 gene in zebrafish represent lineage-specific duplication 





Figure 2.5. Phylogeny supports the classification of zebrafish TLR4 genes as 
orthologs despite genomic relocation. A) Maximum likelihood phylogeny of TLR4 
and RP105. Wedges are collapsed clades of orthologs, with wedge height 
corresponding to the number of included taxa and wedge length indicating the longest 
branch length with the clade. Support values are SH-supports calculated using an 
approximate likelihood ratio test. Clades are colored to highlight TLR4 and RP105 
classification. The taxa included in each clade are noted on the tree by silhouettes of 
mammals (mouse), sauropsids (chicken), amphibians (frog), and fish (zebrafish). B) 
Schematic representation of alternate interpretations of the synteny observations for 
fish TLR4. Synteny for TLR4 is conserved in amniotes, at least partially in 
amphibians, and minimally in gar. While the orthology hypothesis requires a single 
genomic relocation event, the paralogy hypothesis requires a number of independent 




We next revisited the evidence from synteny. The zebrafish TLR4 genes are 
collinear on chromosome 13, suggesting that the three copies arose by tandem gene 
duplication (Fig. 2.5B). This is supported by our ML tree, in which TLR4a and TLR4b 
are sister to one another, but inside the genes from pike and gar (Fig. 2.5A).   
The primary question is whether the gene that eventually became tlr4ba, tlr4a1, 
and tlr4bb duplicated before or after the speciation of bony fishes and tetrapods. The gar 
(Lepisosteus oculatus) genome provides an excellent tool with which to ask this question, 
as the gar is an early-branching bony fish. In tetrapods, TLR4 is consistently flanked by 
the genes trim32 and brinp1 (Table AA2). The gar tlr4 gene, found on linkage group 21 
is upstream of brinp1, like tetrapod tlr4. Further, many additional genes on linkage group 
21 in gar are homologous to genes on chromosome 9 in humans, where human tlr4 is 
located. The co-occurrence of these two genes is strong evidence that the gar TLR4 gene 
is orthologous to the tetrapod TLR4 (Fig. 2.5B).  
Fig. 2.5B shows two trees, corresponding to the two evolutionary scenarios under 
consideration. In the orthology tree, the tlr4 gene moved its location after the speciation 
of gar and zebrafish. This could have occurred, for example, via gene duplication, 
followed by loss of the gene in the original location. All of these gene copies are, 
however, co-orthologous to the tetrapod tlr4. In the paralogy tree, a gene duplication 
even preceded the speciation event separating tetrapods from bony fishes. This was then 
followed by three independent losses: a loss of the tetrapod tlr4 on the bony fish lineage 
(after speciation of the gar), a loss of the tetrapod tlr4 on the gar lineage, and a loss of the 




Based on this analysis, it is more parsimonious to place the zebrafish genes as co-
orthologs of tetrapod tlr4 than to posit an ancestral gene duplication event and differential 
loss along the tetrapod and teleost lineages. This is also consonant with the maximum 
likelihood phylogeny (Fig. 2.5A). Thus, although the genes surrounding the zebrafish tlr4 
genes are different than those surrounding the gar and tetrapod tlr4 genes, the simplest 
interpretation of the available evidence is that the zebrafish tlr4 are orthologs—not 
paralogs—to tetrapod tlr4.  
 
DISCUSSION 
This study provides the first evidence for LPS recognition by TLR4 outside of 
amniotes. We show that zebrafish TLR4a is capable of LPS sensing just as has been 
observed for mammalian TLR4. This is contrary to previous work which concluded a 
lack of LPS sensing by zebrafish TLR4 and therefore an alternate mechanism for LPS 
sensing in fish. 
We report the identification of MD-2 in amphibians and fish. The lack of TLR4 in 
some fish species, the fact that MD-2, despite being only ~160 amino acids, contains 5 
exons and the significant amount of divergence may have contributed to the difficulty 
others had previously in identifying a putative MD-2 transcript. Given the minimal 
conservation across the vertebrate MD-2s, examination of shared features will likely be 
useful in identifying the minimal molecular framework for MD-2 function. 
Phylogenetic analysis and functional conservation support the classification of 
zebrafish TLR4 as orthologous to mammalian TLR4s. Previous studies have suggested 




of tlr4 in some fish species110 and the lack of conserved synteny were consistent with a 
paralogy hypothesis94. The paralogy hypothesis led many to consider the possibility that 
TLR4 may perform an alternate function in fish. However, the identification of MD-2, an 
essential adaptor protein for TLR4 function in mammals, led us to revisit this idea. Given 
the minimal syntenic conservation in gar and the functional conservation of zebrafish 
TLR4, we propose that zebrafish TLR4 is orthologous to mammalian TLR4 and that 
there was a translocation event in the teleost lineages and a subsequent loss of TLR4 in 
some fish species.  
There are several known examples of ligands and inhibitors of the TLR4/MD-2 
complex in mice that behave differently in humans88,111,112. Our previous work examining 
the cross-reactivity of TLR4/MD-2 complexes across the amniotes seemed to suggest 
significant lineage-specific coevolution of these proteins across amniotes; but, the ability 
of mouse and opossum MD-2 to complement zebrafish TLR4a indicates that coevolution 
between TLR4 and MD-2 is not a general trend but instead occurred along specific 
lineages. The differences in cross-specificity of the human proteins may parallel unique 
agonist/antagonist profiles that have previously been observed for human and mouse 
proteins. Further examination of the molecular basis for coevolution at the TLR4/MD-2 
interface in humans may be informative in dissecting the mechanistic basis of species-
specific activation.  
The supporting players for LPS recognition in fish, outside of the TLR4/MD-2 
complex, are not known. We were unable to identify a CD14-like molecule in fish. In 
mammals, CD14 works in tandem with lipid binding protein (LBP) to deliver LPS to the 




identified in fish, the closest protein appears to be a homolog for mammalian bactericidal 
permeability-increasing protein (BPI)99. BPI shuttles LPS to high-density lipoproteins 
instead of to the TLR4/MD-2 complex36,113,114. Fish have previously been shown to be 
resistant to septic shock110,115. High concentrations of LPS are needed to activate teleost 
leukocytes105,116–118. The lack of CD14 and LBP, which increase responsiveness to LPS, 
could explain the lower sensitivity to LPS observed in teleost species.  
These data provide a functional test for zebrafish MD-2 ex vivo, the next logical 
step is to examine if zebrafish MD-2 is important for LPS sensitivity in vivo. This work is 
ongoing, members of the Guillemin lab have generated a CRISPR knockout of zebrafish 
MD-2 and are currently comparing LPS sensitivity of this line to wild-type fish. This 
work will reveal if MD-2 plays the same role in septic shock in zebrafish as it does in 
mammals. 
Zebrafish are popular as model organisms for immunological studies. The data 
presented here show that the TLR4/MD-2 complex is functionally conserved in early 
diverging vertebrates. We have shown that zebrafish can respond to LPS through a 
similar mechanism as observed in mammals. Further, the cross-reactivity of mammalian 
MD-2s and CD14s indicate that despite low sequence conservation in these proteins in 
vertebrates the molecular mechanism of activation also appears to be well conserved. 
Zebrafish may provide a powerful platform for studying TLR4-dependent inflammatory 
processes and septic shock in the future.  
 





We constructed curated databases of TLR4, RP105, MD-2 and MD-1 across the 
vertebrates. We obtained amino acids sequences of these proteins from NCBI, Ensembl, 
Fish1TK, amphibian transcriptomes106–109, UniProt, and ZFIN. We constructed a multiple 
sequence alignment for TLR4 and RP105 and for MD-2 and MD-1 using 
MSAPROBS119, followed by manual editing in MEGA120. We trimmed the alignment to 
remove highly variable (and therefore unalignable) regions. We used PHYML121,122 with 
subtree pruning and re-grafting to construct the ML phylogeny. Pilot analyses revealed 
that the JTT substitution model with 8 rate categories and a floating gamma distribution 
parameter yielded the highest likelihood trees123–125. An AIC test was used to control for 
overfitting126. We rooted our trees at the duplication of these proteins in early vertebrates.  
 
Cell culture and Transfection Conditions 
Mammalian expression vectors containing human TLR4 and mouse TLR4 were 
obtained from Addgene (#13085 and #13086), originally deposited by Ruslan Medzhitov. 
Human CD14 and ELAM-Luc were also obtained from Addgene (#13645 and #13029) 
originally deposited by Doug Golenbock. Human MD-2 was obtained from the DNASU 
Repository (HsCD00439889) and contains a C-terminal V5-tag. Mouse MD-2 (UniProt 
#Q9JHF9) and CD14 (UniProt #P10810), as well as opossum MD-2 (UniProt #F6QBE6), 
CD14 (NCBI Accession #XP_007473804.1) and chicken MD-2 (UniProt 
#A0A1D5NZX9), and CD14 (UniProt #B0BL87) were designed to be free of restriction 
sites and codon optimized for human expression and purchased as mammalian expression 
vector constructs in pcDNA3.1(+) from Genscript (New Jersey, USA). Zebrafish TLR4a 




optimized. Zebrafish TLR4b was a gift from Carol Kim, we re-cloned this protein from 
its original vector into pcDNA3.1(+) to limit variability in expression due to differences 
in vector size and promoter.  
Human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in DMEM supplemented with 10% FBS at 37o C with 5% 
CO2. For each transfection, a confluent 100 mm plate of HEK293T/17 cells was treated at 
room temperature with 0.25% Trypsin-EDTA in HBSS and resuspended with an addition 
of DMEM + 10% FBS. This was diluted 4-fold into fresh medium and 135 µL aliquots of 
resuspended cells were transferred to a 96-well cell culture treated plate. Transfection 
mixes were made with 10 ng of TLR4, 1 ng of CD14, 10 ng of MD-2, 1 ng of Renilla, 20 
ng of ELAM-Luc, and 58 ng pcDNA3.1(+) per well for a total of 100 ng of DNA, diluted 
in OptiMEM to a volume of 10 µL/well. To the DNA mix, 0.5 µL per well of PLUS 
reagent was added followed by a brief vortex and RT incubation for 10 min. 
Lipofectamine was diluted 0.5 µL into 9.5 µL OptiMEM per well. This was added to the 
DNA + PLUS mix, vortexed briefly and incubated at RT for 15 min. The transfection 
mix was diluted to 65 µL/well in OptiMEM and aliquoted onto a plate. Cells were 
incubated with transfection mix overnight (20-22 hrs) and then treated with LPS. E. coli 
K-12 LPS (tlrl-eklps, Invivogen) was dissolved at 5 mg/mL in endotoxin-free water, 
aliquots were stored at -20o C. To avoid freeze-thaw cycles, working stocks of LPS were 
prepared at 10 ug/mL and stored at 4o C. To prepare treatments, LPS was diluted in 25% 
phosphate buffered saline, 75% DMEM. Cells were incubated with treatments for 4 hr. 
The Dual-Glo Luciferase Assay System (Promega) was used to assay Firefly and Renilla 




Firefly luciferase activity/Renilla luciferase activity, normalized to the buffer treated 
transfection control to compare fold-change in NF-kB activation for treatments. 
 
BRIDGE TO CHAPTER III 
 In this chapter, we identified the first MD-2 outside of amniotes and showed that 
MD-2 is present in amphibians and fish. We validated that zebrafish MD-2 supports LPS 
recognition by zebrafish TLR4. This indicates that LPS signaling, and therefore 
recognition of exogenous danger signals, by TLR4 occurs across vertebrates. We next set 
out to determine when endogenous danger signal recognition by TLR4 evolved. S100A9 
is an important pro-inflammatory molecule which activates TLR4 by a direct mechanism. 
S100A9 is specific to mammals. Chapter III describes how we identified MRP-126, an 
S100A9-ortholog in sauropsids, and validated that it activates TLR4. This work 







COEVOLUTION OF THE TOLL-LIKE RECEPTOR 4 COMPLEX WITH 
CALGRANULINS AND LIPOPOLYSACCHARIDE 
 
This chapter contains co-authored material. This chapter was published as Loes, A.N., 
J.T. Bridgham, M.J. Harms. 2018. “Coevolution of the Toll-like receptor 4 complex with 
calgranulins and lipopolysaccharide”. Front. Immunol. 9:304. This chapter was written 
by me with editorial assistance M.J. Harms and experimental expertise from J.T. 
Bridgham.  
INTRODUCTION 
Calgranulin proteins—including S100A8, S100A9, and S100A12—potently 
activate inflammation via an interaction with Toll-like receptor 4 (TLR4)47,61,63,68,127–130. 
These Damage Associated Molecular Pattern (DAMP) proteins play important roles in 
wound healing and vascular development, but can also lead to upregulation and 
amplification of the inflammatory response in arthritis, atherosclerosis, and inflammatory 
bowel disease62,66,131–135. S100A9 has been identified as a potential drug target for 
inhibiting inflammation via inhibition of this pathway68,136. The molecular basis of 
calgranulin activation of TLR4 is not well understood but involves direct binding of the 
calgranulin to the TLR4/MD-2/CD14 complex in a calcium and zinc-dependent 
manner68,137.  
Calgranulin activation of TLR4 is often compared to lipopolysaccharide (LPS) 
activation of TLR447,68,127. LPS is a Pathogen Associated Molecular Pattern (PAMP) 




well understood31: CD14 binds to LPS and loads it on to an MD-2-TLR4 complex21,25. 
This induces a conformational change that leads to homodimerization of TLR4/MD-2 
and triggers an NF-κB cascade23,32. In some ways, calgranulin activation is similar. 
S100A9 has been shown to directly interact with CD14 as well as the TLR4/MD-2 
complex, possibly indicating a similar mechanism of activation68,137. In other ways, 
however, it is quite different. Most notably, LPS is a small molecule that is enveloped by 
MD-2—an unlikely activation pathway for a calgranulin protein21,29,111,138–140. Further, 
LPS and calgranulins induce distinct downstream inflammatory responses, suggesting 
different modes of action63,141.  
A better understanding of the differences between LPS and calgranulin activation 
of TLR4 may reveal the unique requirements for calgranulin activation of TLR4. This 
could allow elucidation of the molecular mechanism of calgranulin activation. Further, 
the ability to independently modulate PAMP and DAMP activity could allow suppression 
of pathological DAMP inflammation independently of the pathogen response. 
An evolutionary lens provides a powerful means for dissecting these similarities 
and differences. Comparison of orthologs from different species is a natural way to reveal 
conserved—and presumably important—features of both DAMP and PAMP activation of 
TLR4. Additionally, studies of coevolution between the TLR4, MD-2, CD14, and 
calgranulins may reveal important species-specific interactions that, in turn, provide 
insight into the mode of activation for each agonist.  
We set out to determine whether calgranulin activation of TLR4 was present 
outside of mammals. While LPS activation of TLR4 has been validated across 




mammals61,68. Using a combination of phylogenetics and functional characterization of 
amniote orthologs, we establish that calgranulin activation of TLR4 evolved at least in 
the last common ancestor of all amniotes. While the basic mode of action is conserved, 
complementation experiments reveal extensive coevolution between TLR4 complex 
members over time. Crucially, coevolution of components in this complex has different 




Calgranulins are found across the amniotes 
We first asked when the calgranulin proteins evolved. Calgranulins are members 
of the S100 protein family144,145. Previous phylogenies of the family allowed us to 
identify the close evolutionary relatives of mammalian calgranulins 144,146,147 but did not 
provide sufficient resolution to dissect the calgranulin clade itself. We constructed a 
curated multiple sequence alignment of 172 protein sequences from 30 species. All 
sequences were close homologs of the calgranulins, with the exception of S100B 
sequences included as an outgroup. We constructed a maximum-likelihood phylogeny for 
these proteins. This revealed eight well-supported clades corresponding to the paralog 
sequences we selected when we built the alignment (Fig. 3.1A). The mammalian 
calgranulins (S100A8, S100A9 and S100A12) formed a clade with MRP-126, a protein 





Figure 3.1. Phylogeny and synteny of the S100 family reveal a bird/reptile 
ortholog for mammalian calgranulin clade. A) Maximum-likelihood phylogeny of 
172 sequences from 30 taxa for proteins within a subclade of the S100 family. C-
terminal tails of sequences were truncated prior to resolving the phylogeny. Wedges 
are collapsed clades of orthologs, with wedge height corresponding to the number of 
included taxa and wedge length indicating the longest branch length with the clade. 
Support values are SH-supports calculated using an approximate likelihood ratio test. 
Clades are colored to highlight calgranulins (red) or S100A7/A15 (orange). The taxa 
included in each clade are noted on the tree. B) Genomic organization of S100 genes in 
amniote species. Arrows for genes represent the coding strand. Approximate distances 
between genes are represented by the length of line for the selected chromosome. 
Mouse and chicken chromosomes were flipped to place A6 in the same orientation 
between species. Colors indicate orthology: calgranulins (red), A7/A15 (orange), A6 
(blue), A5 (light green), and A4 (dark green). Solid lines between genomes indicate 
well-supported orthology from the phylogenetic tree. Dashed lines indicate ambiguous 
orthology. Panels c), d) and e) show possible relationships between MRP-126 and the 
mammalian calgranulins. Mammalian calgranulins are denoted as X, Y, and Z. 
(Because their branching is ambiguous, we cannot resolve which letter represents 
which mammalian calgranulin in these trees). Icons indicate evolutionary events: 
speciation (yellow circle), duplication (green circle), or loss on sauropsid lineage 
(purple diamond). The panels are arranged from most parsimonious to least 
parsimonious. Note that, in the tree shown (a), two marsupial proteins are grouped 
within the sauropsid MRP-126 clade. These are likely marsupial S100A12, which 
would be consistent with their location in the genome (b) and the lack of other 
marsupial S100A12 genes. In our more extensive analyses, the placement of these 






To validate the close relationship between these proteins, we examined the 
organization of these genes in the human, mouse, opossum, duck, and chicken genomes. 
We found that these genes exhibit synteny with one another, consistent with their 
placement together in the model-based phylogenetic analyses (Fig. 3.1B). In humans, the 
genes encoding S100A8, S100A9 and S100A12 are near the 5’ end of a contiguous 
cluster of S100 genes, flanked on the 3’ end by S100A6 and S100A4148. MRP-126 exists 
in an identical arrangement in its genome, albeit on the opposite strand (Table AB1). We 
attempted to verify this arrangement held for reptiles, but we were unable to find reptile 
genomes with contigs of sufficient length in this region to confidently assign synteny.  
This analysis establishes MRP-126 as a sauropsid calgranulin; however, 
relationships within the calgranulin/MRP-126 clade were ambiguous. To try to better 
resolve the relationship between the calgranulins, we repeated our phylogenetic analysis 
using both a Bayesian approach and a second maximum-likelihood analysis with a larger 
set of 494 sequences. In both cases, we obtained similar results: S100A8, S100A9, 
S100A12, and MRP-126 form a clade, but these proteins could not be confidently placed 
relative to one another (Fig. AB1). One intriguing observation is that Anolis carolinensis, 
unlike other sauropsids, contains two calgranulin proteins. Both sequences are in our 
large ML tree (Fig. AB1). One protein is placed with other sauropsid MRP-126 proteins 
with high confidence. The other is placed within the calgranulins, but its orthology is 
ambiguous. This could be a lineage-specific duplication, a gene conversion, or a highly 
diverged ortholog to another S100 such as S100A7. 
There are three basic scenarios consistent with our data (shown schematically in 




S100A9 and S100A12 (Fig. 3.1C). This requires two duplication events on the 
mammalian lineage after the divergence of mammals and sauropsids. Alternatively, 
MRP-126 could be orthologous to two of the mammalian proteins, requiring two 
duplication events and one loss (Fig. 3.1D). The least parsimonious scenario would have 
MRP-126 co-orthologous to one mammalian calgranulin. This would require two 
duplications and two losses (Fig. 3.1E). Alternate scenarios exist but require more 
duplications and losses. The first scenario seems most plausible, given its parsimony; 
however, our data are insufficient to fully resolve these relationships. Whatever the 
precise branching pattern within the calgranulin clade, our analysis supports classifying 
MRP-126 as a sauropsid calgranulin.  
Finally, despite extensive BLAST queries, we were unable to locate any 
calgranulin orthologs in amphibians or bony fishes. Because of the large number of high-
quality fish genomes, this likely indicates that calgranulins are specific to tetrapods. 
There are relatively few amphibian genomes, so it remains unclear whether the lack of 
calgranulins in amphibians represents poor sampling or a true origin in the amniote 
ancestor.   
 
Calgranulin DAMP activity exists across amniotes 
Our phylogenetic analyses reveal that calgranulins arose at least in the ancestor of 
amniotes. To determine when DAMP activity evolved, we “walked out” along the tree, 
recombinantly expressing and purifying calgranulin proteins from the human (Homo 
sapiens), mouse (Mus musculus), opossum (Monodelphis domestica) and chicken (Gallus 




are known to be potent DAMPs. We expressed chicken MRP-126 as a representative 
sauropsid calgranulin (Fig. 3.2A). After purification, we verified that all proteins were 
folded using far-UV circular dichroism spectroscopy. As expected for S100 proteins, all 
four proteins gave largely alpha-helical structures (Fig. 3.2B). We also built homology 
models of mouse S100A9, opossum S100A9 and chicken MRP-126 using the human 
S100A9 template (Fig. 3.2C). All these sequences could be readily accommodated in the 
S100 fold.  
Figure 3.2. MRP-126, like mammalian calgranulins, is primarily alpha-helical 
with a disordered C-terminal extension. A) Multiple sequence alignment of 
mammalian calgranulins with chicken MRP-126. Amino acid residues are colored to 
show sites with similar chemical properties. B) Homology model of mouse S100A9 
(green), opossum S100A9 (blue), and chicken MRP-126 (orange) aligned with human 
S100A9 (purple) calcium-bound NMR structure PDB: 5i8n C) Circular dichroism 




We next asked how well each calgranulin could activate via TLR4. We assayed 
the TLR4-dependent activation of the inflammatory NF-κB pathway using an ex vivo cell 
culture assay149,150. We transiently transfected plasmid constructs encoding TLR4 and its 
cofactors MD-2 and CD14 into HEK293T/17 cells. These cells do not natively express 
TLR4, MD-2 or CD14 so TLR4-dependent activation of NF-κB depends on the 
heterologous expression of the transfected TLR4 complex components. We used a 
luciferase gene under the control of an NF-κB promoter as a reporter. The NF-κB 
pathway is conserved across bony vertebrates5, making mammalian cells useful as a 
common host for amniote TLRs. 
We first validated the assay by measuring the known PAMP and DAMP 
activation of TLR4 complexes by the human and mouse proteins47,68,127. We transfected 
genes encoding TLR4, MD-2, and CD14 into cells and measured activity under different 
treatment conditions (Fig. 3.3A, 3.3B). LPS induced significantly higher NF-κB response 
than a mock treatment. The addition of the LPS sequestering agent polymyxin B 
completely abolished this activity. We then treated transfected cells with recombinantly 
expressed S100A9—the most potent DAMP of the mammalian calgranulins. Both the 
human and mouse TLR4 complexes responded robustly to the addition of species-
matched S100A9. All treatment buffers, with the exception of the LPS treatment, 
contained polymixin B to eliminate spurious activation via potential LPS contamination. 
Both LPS and S100A9 activation were strictly dependent on the presence of heterologous 





Figure 3.3. Calgranulin activation of TLR4 is shared across amniotes. NF-κB 
activity for species-matched TLR4/MD-2/CD14 complexes in the presence of 
calgranulins from A) human, B) mouse, C) opossum and D) chicken. A “+” in the table 
below each series indicates which components are included in that treatment. LPS is 
used as a positive control for expression and activation of the complex. Polymixin B is 
included to control for endotoxin-mediated activation of the complex. Activity is 
normalized to LPS activity of positive control within each biological replicate, (i.e. for 
human, each technical replicate is divided by the average LPS activation of hTLR4, 
hMD2, and hCD14 for that biological replicate). Points are the technical triplicates 
from three biological replicates. Bold lines are the mean of the biological replicates. 
Error bars are a standard error on the mean of the biological replicates. A two-tailed t-
test was used to assess the significance of the difference in mean between the indicated 
series (**p-value < 0.01).  
 
With the assay validated, we then turned our attention to the TLR4 complex from 
other amniotes. We started by assessing a marsupial, the opossum. TLR4, MD-2, CD14, 
and S100A9 are known to be expressed in marsupials151,152, but their activity had not 
been characterized for LPS or DAMP activation. We transfected opossum TLR4 complex 
components and treated them with both LPS and recombinant opossum S100A9. We 
found an identical pattern of activation for the opossum proteins relative to those from 
human and mouse (Fig. 3.3C).  
We next assessed the activation of the chicken TLR4 complex by LPS and MRP-
126. Chicken MRP-126 is known to have a similar expression profile to mammalian 
calgranulins, with upregulated expression during bacterial infection92,153, suggesting it 




functionally characterized for a role in LPS activation92,154. We transfected TLR4 
complex components from the chicken. We observed an identical pattern of activation for 
the chicken as for the mammalian proteins for activation of the chicken TLR4 complex 
by LPS and recombinant MRP-126. (Fig. 3.3D). 
 
Figure 3.4. Amniote calgranulins have similar TLR4 complex requirements. NF-
κB activation of TLR4 from A) human, B) mouse, C) opossum and D) chicken. NF-κB 
is normalized to LPS activation of the control complex for that species. Points are the 
technical replicates from three biological replicates. Bold lines are the mean of the 
biological replicates. Error bars are a standard error on the mean of the biological 
replicates. A “+” in the panel below indicates which components are included in the 
treatment. A two-tailed t-test was used to assess the significance of the difference in 
mean between the indicated series (**p-value < 0.01). 
 
Calgranulins from across the amniotes activate TLR4 in a similar fashion 
We next determined whether the same components were necessary and sufficient 
for calgranulin activation of TLR4 across the amniotes. Shared complex requirements are 
strong evidence for a common, ancestral mode of action. We first measured the ability of 




and without the cofactors MD-2 and CD14 present. We found that MD-2 was required 
for calgranulin activation of TLR4 in all species, as no MD-2-independent signaling was 
observed for any species tested (Fig. 3.4). CD14 also strongly contributed to signaling. 
This is consistent with previous observations that CD14 is involved in TLR4-dependent 
NF-κB signaling by human S100A9137. Some CD14-independent NF-κB signaling was 
observed in the human and mouse proteins; however, the addition of CD14 drastically 
improved the signal for activation. No significant signaling was observed for the 
opossum or chicken proteins in the absence of CD14 (Fig. 3.4).  
 
Figure 3.5. TLR4 complex components exhibit lineage-specific coevolution. 
Subpanels show activation of NF-κB signaling by receptor complexes assembled from 
host (black) and guest (red) proteins. Protein names on the left and top of each sub-
panel indicate the components included. S100 is used to denote human S100A9, mouse 
S100A9, opossum S100A9 or chicken MRP-126. Letters indicate which species 
components come from human (H), mouse (M), opossum (O), or chicken (C). If the 
cross-species complex activates >2-fold above the buffer control, the corresponding 
box is filled gray. The icon to the top-left of each sub-panel indicates graphically which 
components are being combined. * indicates >2-fold activation above buffer control, 




We next tested whether calgranulins from across the amniotes could complement 
one another. We treated the TLR4 complex from each species with recombinant 
calgranulin from each species and then measured activation. We found that all 
calgranulins could activate all complexes (Fig. 3.5A), again supporting a shared ancestral 
mode of action. Dose-responsive activation occurs at concentrations in the micromolar 
range for all calgranulins against amniote TLR4/MD2/CD14 complexes (Fig. AB2).  
 
Calgranulins and LPS signaling have overlapping, but different molecular 
requirements 
Coevolution can lead to species-specific interactions that, in turn, reveal key 
determinants of activation139,143. The cross-reactivity of calgranulins against TLR4 
complexes from different species reveals a shared mode of action; however, we were also 
interested in identifying any species-specific differences in activation. We, therefore, 
searched for coevolution between the calgranulins and members of the TLR4 complex. 
We took a complementation approach, adding a guest component from one species into a 
host complex of components from a different species (Fig. 5, AB3-AB8). We used this 
approach to test for lineage-specific evolution between TLR4, MD-2, CD14, and the 
calgranulins.  
We first tested whether host-guest complexes were competent for LPS signaling. 
We used CD14 (Fig. 3.5B), MD-2 (Fig. 3.5C) and TLR4 (Fig. 3.5D) as guests and then 
measured activation upon the addition of LPS. We found that CD14 was non-specific and 




specificity for CD14 is consistent with it acting as a peripheral protein that delivers LPS 
to the central TLR4/MD-2 complex100,155.  
In contrast, MD-2 and TLR4 exhibited strong species-specific variability in 
activation: many host-guest pairs were incompatible (Fig. 3.5C, 3.5D). The only proteins 
that could complement one another fully were the mouse/human and mouse/opossum 
pairs. Further, MD-2 and TLR4 gave essentially identical patterns of compatibility 
between species. This indicates strong coevolution between these two proteins. This 
likely arises as a result of the large, functionally critical interface formed between TLR4 
and MD-220,21,23,29,139,156. 
We repeated these experiments using calgranulins rather than LPS to activate the 
complex. We used calgranulin matched to the host complex and added guest CD14 (Fig. 
3.5E), MD-2 (Fig. 3.5F), and TLR4 (Fig. 3.5G). This revealed a similar pattern to that of 
LPS signaling. CD14 was relatively nonspecific (Fig. 3.5E), while MD-2 and TLR4 were 
highly specific (Fig. 3.5F, 3.5G). Indeed, the MD-2/TLR4 pattern of activation for 
calgranulins was identical to that of LPS, with the exception of the human-mouse and 
mouse-opossum heterocomplex. A similar pattern was observed when examining 
activation by the calgranulin matched to the guest component (Fig. 3.5H-J).  
The host-guest combinations that do not activate with either LPS or calgranulin 
likely fail to assemble into a productive complex, independent of the nature of the pro-
inflammatory signal. The failure of the mouse-opossum complexes for calgranulin but 
not LPS, however, indicates that there are different requirements to activate the complex 
via LPS or calgranulins. This can be seen with a more detailed comparison of the 




stand in for mouse MD-2 for LPS signaling (Fig. 3.6A), but not for calgranulin signaling 
(Fig. 3.6B, 3.6C). This reveals that these two pro-inflammatory signals activate 
differently, despite identical complex requirements (Fig. 3.4).  
 
Figure 3.6. LPS and calgranulin exhibit different complex requirements. Panels a-
c show NF-κB activation of mouse TLR4 with different combinations of mouse and 
opossum MD-2 and CD14. Activation by: A) LPS, B) mouse S100A9, and C) opossum 
S100A9. Panels D-F show NF-κB activation of human TLR4 with different 
combinations of human and mouse MD-2 and CD14. Activation by: D) LPS, E) human 
S100A9, and F) mouse S100A9. Letters indicate which species the component was 
taken from: human (H), mouse (M) or opossum (O). NF-κB is normalized to LPS 
activation of the control complex for that species. Points are the technical triplicates 
from three biological replicates. Bold lines are the mean of the biological replicates. 
Error bars are a standard error on the mean of the biological replicates. A “+” in the 
panel below indicates which components are included in the treatment. A two-tailed t-
test was used to assess the significance of the difference in mean between the indicated 
series (*p-value < 0.05, **p-value < 0.01). 
 
There were also quantitative differences between LPS and calgranulin activation 




LPS activation of human TLR4 (Fig. 3.6D). In contrast, mouse MD-2 is less efficient 
than human MD-2 for calgranulin activation of the complex (Fig. 3.6E, 3.6F). 
Intriguingly, this difference can be offset by the addition of the mouse CD14 in addition 
to mouse MD-2 (Fig. 3.6E, 3.6F). This interaction between MD-2 and CD14 reveals that 
both components are important for calgranulin activation of TLR4 and that their roles are 
different for LPS and calgranulin.  
Our analysis reveals lineage-specific coevolution between complex members. The 
dominant signal for coevolution is between TLR4 and MD-2. This impacts both LPS and 
calgranulin activation, likely because the interaction between MD-2 and TLR4 is 
important for complex assembly. There are, however, differences between which host-
guest complexes are sensitive to LPS and calgranulins, revealing that LPS and 
calgranulins activate these complexes in subtly different ways. These differences may 
indicate that the interface calgranulins interact with has independent molecular 
requirements from LPS, possibly spanning components or inducing an alternate active 
conformation than LPS. 
 
DISCUSSION 
Our work reveals that the calgranulin (DAMP) and LPS (PAMP) activation of 
TLR4 evolved at least as early as the ancestor of amniotes. As all amniote calgranulins 
we tested activate their species-matched TLR4, this activity likely arose before the 
divergence of amniotes and mammals ~320 million years ago. Like LPS, activation of 




by the cofactor CD14. These shared cofactor requirements suggest that both DAMP and 
PAMP use conserved, ancestral modes of activation.  
We also find that DAMP and PAMP activation must occur via slightly different 
pathways. This can be seen in our complementation experiments. While opossum MD-2 
can complement mouse MD-2 for LPS activation, it cannot complement mouse MD-2 for 
calgranulin activation. Likewise, mouse MD-2 requires mouse CD14 for calgranulin 
activation of human TLR4. These results could point to a direct interaction between MD-
2 and S100A9 or a multi-way interaction between TLR4/MD-2/CD14 and calgranulins. 
Further analysis may help identify the residues involved in the TLR4/MD-2/calgranulin 
interface, as has been done for the MD-2/TLR4 interface by comparing human and other 
species activation by LPS111,143. Alternatively, this signal may be mediated indirectly, via 
the dimerization of TLR4/MD-2 – activation of TLR4 requires dimerization of 
TLR4/MD-2, in part, mediated by residues on MD-221,22,32,156.  
We found that calgranulins are broadly cross-reactive to TLR4 across the 
amniotes. This is consistent with a fairly non-specific mechanism of action, such as 
binding via a non-specific hydrophobic patch on the calgranulin surface. Hydrophobicity 
has been proposed to be an important global danger signal – exposure of hydrophobic 
regions of folded proteins is an indicator of damage157. If a non-sequence dependent 
mechanism of activation, like hydrophobicity, is employed by the calgranulins for TLR4 
activation, this may be a co-opted signaling mechanism which evolved prior to the 
calgranulins and is employed by other endogenous danger signals for TLRs.  
It remains an open question when LPS activation evolved relative to calgranulin 




PAMP activation. TLR4 is expressed in bony fishes, but the ligand for this receptor is 
unknown. If another class of hydrophobic DAMP activates TLR4 in fish, DAMP 
activation of TLR4 may even predate amniotes. We do not yet know when LPS 
activation of TLR4 evolved. Resolving if DAMP activation evolved prior to PAMP 
activation will require studying TLR4 activation in amphibians and bony fishes. 
Previous studies have investigated the ability of zebrafish TLR4 to activate NF-
kB signaling in response to LPS93,94,110. Because no orthologs to mammalian MD-2 and 
CD14 have been identified outside of amniotes, the researchers used mammalian CD14 
and MD-2 in their experiments with zebrafish TLR4s. They observed no response to 
LPS. One interpretation of this result is that fish do not respond to LPS via TLR4. An 
observation that may support this is the loss of TLR4 in many fish lineages93,94,110. Our 
complementation studies suggest that MD-2 coevolution with TLR4 would likely prohibit 
cross-reactivity of mammalian MD-2 with fish TLR4, even if fish possessed a functional 
MD-2-like cofactor. LPS activation of TLR4 in fishes should thus be reexamined. This 
will, however, require identification of TLR4 cofactors from fish—if they exist—rather 
than cofactors from tetrapods.  
Our experiments and evolutionary analysis have revealed that calgranulin 
activation of TLR4 evolved at least 180 million years earlier than previously appreciated. 
These results show that DAMP recognition occurred through TLR4 at least in early 
amniotes. For many years, the predominant theory of the innate immune system was that 
its primary role was to discriminate “self” from “non-self”. In the 1990’s, Matzinger 
proposed the danger hypothesis158 – which describes the innate immune system as a 




endogenous signals indicative of damage. Our results are consistent with an ancient, 
general danger-sensing function for TLR4: at least across amniotes TLR4 plays a role in 
combating danger, not simply as a mechanism to distinguish "self" and "non-self".  
 
MATERIALS & METHODS 
Phylogenetics and genomic analysis 
We constructed a curated database of S100 homologs from a consistent set of 
species. We obtained amino acids sequences of S100 proteins from a subset of the 
amniote species in Ensembl version_87159. We obtained additional bird and reptile 
S100A7 and MRP-126 sequences using the human calgranulin paralogs to BLAST 
against the NCBI database. This yielded a set of 172 sequences from 30 taxa (Data Sheet 
S1, S3). We constructed our multiple sequence alignment using MSAPROBS119, 
followed by manual editing in MEGA120. We trimmed the alignment to remove highly 
variable (and therefore unalignable) C-terminal extensions, as well as the non-S100 
domains of the fused S100 proteins. We used PHYML-SS121,122 with subtree pruning and 
re-grafting to construct the ML phylogeny. Pilot analyses revealed that the LG 
substitution model with 8 rate categories and a floating gamma distribution parameter 
yielded the highest likelihood trees123–125. An AIC test was used to control for 
overfitting126. We rooted our trees using the divergence of S100B, an ancient S100 found 
across jawed vertebrates. These steps were repeated with a set of 494 sequences 
representing all amniote S100s within this clade of the S100 family (Data Sheet S2, S4, 




We constructed our Bayesian tree using ExaBayes160 using a single data partition, 
integrating over tree topologies, rates, and evolutionary models. We ran two replicate 
analyses, using three heated chains and a single cold chain per replicate. We ran for 5.6 
million rounds, with a final average difference between replicates of 0.6 %. We discarded 
the first 15% of the analysis as burn-in and generated a 50% majority-rule consensus tree. 
The syntenic analysis was done using the Ensembl synteny module161 to map 
orthologs and homologs onto the chromosomes of species of interest (Table AB1). The 
genome assemblies were Homo sapiens (GRCh38.p10; GCA_000001405.25), Mus 
musculus (GRCm38.p5; GCA_000001635.7), Monodelphis domestica (monDom5; 
GCF_000002295.2), Anas platyrhynchos (BGI_duck_1.0; GCA_000355885.1), and 
Gallus gallus (Gallus_gallus-5.0; GCA_000002315.3). We attempted to include 
representative reptile genome; however, the S100 genes of interest were found on 
different contigs in the available reptile genomes.  
 
Plasmids and recombinant protein preparation and characterization 
Mammalian expression vectors containing human TLR4 and mouse TLR4 were a 
gift from Ruslan Medzhitov (Addgene plasmid #13085 and #13086) and human CD14 
and ELAM-Luc were a gift from Doug Golenbock (Addgene plasmid #13645 and 
#13029). Human MD-2 was obtained from the DNASU Repository (HsCD00439889). 
Mouse MD-2 (UniProt #Q9JHF9) and CD14 (UniProt #P10810), as well as opossum 
TLR4 (UniProt #F6Y6W8), MD-2 (UniProt #F6QBE6), CD14 (NCB Accession 
#XP_007473804.1) and chicken TLR4 (UniProt #C4PCF3), MD-2 (UniProt 




sites and codon optimized for human expression and purchased as mammalian expression 
vector constructs in pcDNA3.1(+) from Genescript (New Jersey, USA).  
Synthetic gene constructs for human (UniProt #P06702), mouse (UniProt 
#P31725), and opossum (UniProt #F7AJJ0) S100A9 and chicken MRP-126 (UniProt 
#P28318), were also designed to be free of common restriction sites and codon optimized 
and purchased as PUC57 constructs from Genewiz (New Jersey, USA). Genes were 
cloned into a modified 6xHis MBP LIC TEV vector with NcoI and HindIII to yield 
protein constructs with TEV-cleavable histidine tags. E. coli BL21(DE3) pLysS 
competent cells containing the expression vectors for S100 proteins were grown 
overnight at 37o C, diluted 1:150 into LB containing ampicillin and chloramphenicol, 
grown to mid-log phase (OD600 ~ 0.6-1), and induced with 1 mM isopropyl-β-d-1-
thiogalactopyranoside overnight at 16o C with aeration. Bacterial pellets were harvested 
by centrifugation at 3000 rpm at 4o C for 20 min and stored at -20o C. Pellets (~5 g) were 
suspended by vortexing and lysed in 25 mL Buffer (25 mM Tris, 100 mM NaCl, 25 mM 
imidazole, pH 7.4) with 37.5 U DNase I (ThermoFisher Scientific) and 0.75 mg 
Lysozyme (ThermoFisher Scientific) by shaking at RT for approximately 1 hr. The lysate 
was clarified by centrifugation at 15,000 RPM for 50 min. at 4o C. Protein was purified 
using a 5 mL Ni2+-NTA HisTrap column from (Healthcare GE) using an FPLC (Akta 
Biosciences) with gradient elution to HisB (25 mM Tris, 100 mM NaCl, pH 7.4, with 500 
mM imidazole for human, mouse and chicken proteins, 1 M imidazole for opossum 
S100A9). Pooled elution peak of purified protein was cleaved with tobacco etch protease 
(TEV) overnight at RT. Cleaved protein was collected from a gradient elution of a 5 mL 




pure fractions were pooled and dialyzed into phosphate buffered saline (PBS), 0.5 mM 
TCEP, pH 7.4. Protein was flash frozen in liquid nitrogen and fresh aliquots were thawed 
weekly for functional assays. TLR4 activation was tested with two independent preps of 
each protein to ensure that the results were not batch specific. Protein concentrations 
were measured using a Bradford assay.  
Homology models of mouse S100A9, opossum S100A9 and chicken MRP-126 
were prepared with Swiss-Model162,163. For secondary structure measurements, protein 
samples were prepared at 10 µM in endotoxin free PBS and far-UV circular dichroism 
data was collected between 200–250 nm using a J-815 CD spectrometer (Jasco) with a 1 
mm quartz spectrophotometer cell (Starna Cells, Inc. Catalog No. 1-Q-1). Duplicate 
scans were collected for each protein and averaged. A blank buffer spectrum was 
subtracted from sample measurements and raw ellipticity was converted into mean molar 
ellipticity using concentration and the number of residues for each protein. 
 
Cell culture and transfection conditions 
Human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in DMEM supplemented with 10% FBS at 37o C with 5% 
CO2. For each transfection, a confluent 100 mm plate of HEK293T/17 cells was treated at 
room temperature with 0.25% Trypsin-EDTA in HBSS and resuspended with an addition 
of DMEM + 10% FBS. This was diluted 4-fold into fresh medium and 135 µL aliquots of 
resuspended cells were transferred to a 96-well cell culture treated plate. Transfection 
mixes were made with 10 ng of TLR4, 1 ng of CD14, 0.5 ng of MD-2, 0.1 ng of Renilla, 




diluted in OptiMEM to a volume of 10 µL/well. To the DNA mix, 0.5 µL per well of 
PLUS reagent was added followed by a brief vortex and RT incubation for 10 min. 
Lipofectamine was diluted 0.5 µL into 9.5 µL OptiMEM per well. This was added to the 
DNA + PLUS mix, vortexed briefly and incubated at RT for 15 min. The transfection 
mix was diluted to 65 µL/well in OptiMEM and aliquoted onto a plate. Cells were 
incubated with transfection mix overnight (18-22 hrs) and then treated with protein (2 
µM) or LPS (100 ng/well) mixtures (prepared in 25% phosphate buffered saline, 75% 
DMEM). E. coli K-12 LPS (tlrl-eklps, Invivogen) was dissolved at 5 mg/mL in 
endotoxin-free water, aliquots were stored at -20o C. To avoid freeze-thaw cycles, 
working stocks of LPS were prepared at 10 ug/mL and stored at 4o C. There has been 
some concern in testing recombinant DAMPs against TLR4 due to the potential presence 
of contaminating LPS in proteins which have been expressed in bacteria 7,9. We tested 
our S100s in the presence of 50 µg/mL polymyxin B, an LPS binding agent to limit 
signaling from LPS contamination in recombinant protein preparations. This 
concentration of polymyxin B, while sufficient to eliminate signaling by 100 ng/mL of 
LPS had a minimal effect on the signaling by calgranulins (Fig. AB9). Cells were 
incubated with treatments for 4 hr. The Dual-Glo Luciferase Assay System (Promega) 
was used to assay Firefly and Renilla luciferase activity of individual wells. Each NF-κB 
induction value shown represents the Firefly luciferase activity/Renilla luciferase activity, 
normalized to the LPS-treated transfection control for each species in order to normalize 
between plates. It should be noted that the level of constitutive activity was different 




For cross-species comparisons, we used an internal standard to account for 
systematic differences in the magnitude of luciferase activation between biological 
replicates. We normalized measured activation values such that the LPS activation of the 
reference gene combination was 1.0. This is an appropriate normalization because we 
only compare the relative activation of gene/activator combinations on the same plate. 
For example, for each biological replicate plate used in the human/mouse 
complementation analysis, we divided the activation of all gene/activator combinations 
on that plate by the LPS activation hTLR4/hMD2/hCD14 observed for that plate. This 
means we are comparing the activation of other combinations (e.g. hA9 activation of 
hTLR4/mMD2/mCD14) relative to the internal standard (LPS activation 
hTLR4/hMD2/hCD14).  
 
BRIDGE TO CHAPTER IV 
 In this chapter, we showed that activation of TLR4 by S100s occurs across the 
amniotes. We also show that S100 activation requires co-factors MD-2 and CD14, and 
that it appears to occur via a conserved, but a non-specific mechanism. Activation of 
human TLR4 by S100A9 has been shown to occur via a calcium and zinc-dependent 
mechanism. Zinc binding, however, has not been well characterized for S100A9 
homodimers. In Chapter IV, we examine zinc binding by S100A9 homodimers and 






ZINC-BINDING AND THE C-TERMINAL TAIL ARE NOT REQUIRED FOR PRO-
INFLAMMATORY ACTIVITY OF S100A9 
 
 
This chapter contains co-authored material. Experiments were performed by me and Ran 
Shi. ICP-MS data was collected by the Elemental Analysis Core at OHSU. This chapter 
was written by me with editorial assistance from Michael J. Harms 
 
INTRODUCTION 
Chronic inflammation is at the root of many human diseases. Targeted disruption 
of inflammatory signaling cascades is a core goal of therapeutic strategies for alleviating 
inflammation. S100A9 is a biomarker for inflammatory diseases62,63,68,127,129 and has been 
identified as a potential therapeutic target68. Deletion of S100A9 in mice has a protective 
effect against septic shock67, as this eliminates the positive feedback loop of chronic 
pathogenic inflammation propagated by S100A9. The potent pro-inflammatory activity of 
S100A9 is mediated through a direct interaction with TLR468. The molecular basis for 
this interaction is not yet known. Understanding the molecular mechanism for S100A9 
activation of TLR4 is important for being able to design targeted inhibitors of this 
interaction to regulate inflammation. 
We can gain some insight into how S100A9 interacts with TLR4 by examining 
other members of the S100 family, which are predominately calcium-regulated signaling 
proteins. Like other members of the S100 family, S100A9 undergoes a characteristic 




hydrophobic surface area164. For many of the S100s, this hydrophobic surface has been 
shown to interact with short linear motifs of target proteins or peptides165–168. Recent data 
also suggests that it is this region of S100A9 that directly interacts with TLR4169. Further, 
the interactions between S100A9 and protein partners require calcium, suggesting 
S100A9 uses a similar binding mechanism for recognition of targets as other 
S100s68,136,170.  
While many S100 proteins bind to transition metals via a canonical site at the 
dimerization interface146, S100A9 is unique in that binding to transition metals has been 
shown to modulate its interaction with protein partners, like Toll-like receptor 4 
(TLR4)68. How zinc regulates interactions between S100A9 and TLR4 is not known. 
Here we set out to characterize how S100A9 interacts with zinc and how zinc binding by 
S100A9 is involved in activation of TLR4. We assessed whether deletion of the C-
terminal extension or mutation of the transition metal binding site altered activation of 
TLR4. These experiments reveal that zinc is not required for activation of TLR4 in a cell 
culture assay either through direct binding or coordination of the C-terminal tail and that 
zinc-dependent aggregation is not required for activation of TLR4.  
 
RESULTS 
S100A9 homodimer binds to zinc 
Zinc binding has not been characterized for the S100A9 homodimer. However, 
transition metal binding by the heterodimer of S100A8 and S100A9, known as 
calprotectin, has been extensively studied171–173. We set out to determine whether 




The heterodimer contains two distinct transition metal binding sites. Histidine 
residues in the C-terminal tail of S100A9 (H91, H95, H103-105) contribute to a high-
affinity six-histidine manganese binding site in calprotectin173 (Fig. 4.1). Additionally, N-
terminal metal-coordinating residues in S100A9 (H20, D30) form part of a tetrahedral 
zinc binding site (Fig. 4.1). We sought to determine whether the zinc-binding sites in the 
S100A9 homodimer resemble either of the sites observed in the heterodimer. We 
designed two mutant constructs (Table AC1) of S100A9, a C-terminal truncation mutant 
(S100A9∆99) and a metal binding mutant where all predicted zinc-coordinating 
histidines were substituted for asparagine, and the N-terminal aspartate was exchanged 
for serine. In our full metal site mutant, S100A9∆Zn, we also chose to mutate the N-
terminal cysteine, as cysteine can coordinate zinc (C3S/H20N/D30S/H91N/H95N/H103-
105N). 
Figure 4.1. Heterodimer crystal structure leads to hypotheses for metal binding 
residues in S100A9 homodimer. Cartoon representations of crystal structures for 
S100A9 homodimer in the presence of calcium (PDB: 1irj)70 and S100A8/S100A9 
heterodimer (PDB:4ggf)171 in the presence of calcium and manganese. The C-terminal 
tail (grey) of S100A9 is disordered in the absence of transition metals but becomes 
structured when histidines in the tail coordinate metal ions. Zinc binding residues of 
S100A9 have been identified for the heterodimer (cyan), mutation of these residues 






Figure 4.2. Metal binding by S100A9 homodimer. A) Metal binding mutants were 
constructed which disrupt zinc binding to S100A9 by ITC. Isotherms for metal binding 
mutants further show the distinct difference between B) wild-type, C) S100A9(C3S), 
D) S100A9(∆99) and E) S100A9(∆Zn). Pictures are included to aggregation that 
occurred for S100A9, S100A9(C3S), S100A9(∆99), but not for S100A9(∆Zn) 
 
We examined zinc-binding to S100A9 in the presence of calcium, using 
isothermal calorimetry (ITC). The isotherm for wild-type S100A9 is consistent with 
binding (Fig. 4.2A, 4.2B). However, aggregation was observed within the sample cell 




reliable Kd. Despite the inability to calculate affinity, these experiments did give some 
insight into zinc binding by S100A9: zinc binding by S100A9 is exothermic, relatively 
low affinity, and appears to occur by two distinct processes.  
To alleviate the aggregation issue, we substituted a serine for the N-terminal 
cysteine of S100A9. Previous studies have shown that an N-terminal cysteine in S100A2 
comprises an additional zinc site which leads to aggregation of the protein. We predicted 
that mutagenesis of the N-terminal cysteine would disrupt aggregation but leave the metal 
binding site intact. However, zinc-binding for S100A9(C3S) was remarkably similar to 
the wildtype protein (Fig. 4.2A, 4.2C). Unfortunately, this mutant was still aggregation-
prone.  
We next tested the ability of the C-terminal truncation mutant, S100A9∆99, to 
bind zinc. Again, we observed aggregation of S100A9(Δ99) within the sample cell. 
However, we do observe a difference in the binding isotherm for the C-terminal 
truncation mutant (Fig. 4.2A, 4.2D), suggesting that the tail participates in zinc binding 
by wild-type protein. Truncation of the C-terminal tail appears to disrupt one of the 
processes involved in zinc-binding by S100A9.  
Finally, we tested the full-metal site mutant of S100A9 – S100A9∆Zn. The ITC 
curve for zinc binding by S100A9(ΔZn) is markedly different from that of both wild-type 
S100A9 and S100A9(Δ99) (Fig. 4.2A, 4.2E). Mutagenesis of the predicted metal binding 
residues in S100A9 appears to fully disrupt zinc binding. Additionally, S100A9∆Zn does 
not aggregate. This suggests that the aggregation observed for S100A9 in the presence of 





Zinc binding to S100A9 results in reversible aggregation 
S100 proteins are aggregation-prone170,174,175. We and others have observed zinc-
dependent aggregation of S100A9 both in vitro and in vivo176. This aggregation behavior 
by S100A9 has been proposed to play a role regulating TLR4 activation170, though it is 
not known whether the aggregate is the active pro-inflammatory complex or if 
aggregation is a mechanism for dampening inflammatory activity of S100A9. 
Aggregation occurs instantaneously at near equimolar concentrations of zinc for protein 
>10 µM. This aggregation was observed for wild-type S100A9 but also occurs with the 
C3S mutant (Fig. 4.2B, 4.2C), indicating that the aggregation behavior is not simply 
dependent on the presence of an N-terminal cysteine as has been proposed for S100A2.  
 
Figure 4.3. Reversible zinc-dependent aggregation of S100A9. A) Reversible 
aggregation of 20 µM S100A9(C3S) B) Aggregation is not observed for S100A9∆Zn. 
CD signal is shown for apo protein (light green) with the addition of 100 µM calcium 
(blue) and 100 µM zinc (yellow) by addition of 500 µM EDTA (dark green). 
 
Our zinc-binding experiments had suggested an apparent loss of zinc-dependent 
aggregation of the S100A9(ΔZn). To examine this aggregation behavior more closely, we 




helical signal upon the addition of zinc. Interestingly, we found that aggregation of 
S100A9(C3S) is fully reversible with the addition of EDTA (Fig. 4.3A). Consistent with 
our ITC experiments, no aggregation was observed for S100A9(ΔZn) (Fig. 4.3B). This 
indicates that the aggregation behavior is a driven by zinc binding to the canonical 
transition metal binding site of S100A9. Given the lack of zinc-dependent aggregation 
observed for S100A9(ΔZn), this mutant allows us to test not only if zinc binding at this 
site is important for activation of TLR4 but also whether aggregation of S100A9 is the 
mechanism for zinc-dependence of TLR4 activation by S100A9.  
 
C-terminal tail and metal binding site of S100A9 are not required for TLR4 activation 
We set out to test two hypotheses for how zinc might regulate the interaction of 
S100A9 with TLR4. First, the unique-to-the-family flexible C-terminal extension of 
S100A9 is proximal to the putative protein target binding region and disordered in the 
absence of transition metal (Fig. 4.1). Structuring of the C-terminal tail upon transition 
metal binding has been observed for the heterodimer of S100A8 and S100A9171–173. This 
structural rearrangement is a possible mechanism for zinc regulation of protein 
interactions for S100A9: The structured C-terminal tail may directly comprise part of the 
target binding surface, or alternatively, the disordered tail may inhibit target interactions 
in the absence of zinc by occluding the target binding surface. Zinc might also regulate 
the interaction between S100A9 and TLR4 via a non-tail-dependent mechanism, such as 
oligomer formation or aggregation. We set out to test these hypotheses for zinc-
dependent activation of TLR4 by S100A9 using our zinc binding mutant and our C-





Figure 4.4. Zinc binding mutant is capable of activation of TLR4. We see no 
difference in activation of TLR4 following mutagenesis of the zinc binding site in 
S100A9. Activation by wildtype S100A9 (purple), S100A9(Δ99) (grey) and 
S100A9(ΔZn) (cyan) against human TLR4/MD-2/CD14 complex. Proteins were tested 
in the presence of polymixin B (PMB). Points show technical triplicates from 
biological replicates. Error bars show a standard error on the mean, mean is shown a 
horizontal line.  
 
We observed that there was no difference in activation of TLR4 between wild-
type S100A9 and S100A9(Δ99) (Fig. 4.4). This indicates that the C-terminal extension of 
S100A9 is not essential for activation of TLR4. However, we also considered that, in the 
absence of zinc, the C-terminal tail may be transiently obstructing the hydrophobic 
surface which has been shown in many S100s to be important for interacting with protein 
targets and has recently been shown to be important for the interaction between S100A9 
and TLR4169. Consistent with this hypothesis, recent work examining the interaction of 
RAGE and S100A9 with HSQC has shown that binding of RAGE to S100A9 results in 
an increase in the peak intensities of the tail residues of S100A9177. For a disordered 
structure, this is consistent with a decrease in conformational dynamics. Binding to 




If the tail is playing a transient role in obstruction of that surface, then we might 
expect truncation of the tail not to alter the interaction with TLR4. However, we may see 
a loss of activity if the tail was no longer able to bind to transition metals. Our metal 
binding mutant provided a means to test this hypothesis. To our surprise, we did not 
observe a significant difference in activation of TLR4 between S100A9 and 
S100A9(ΔZn) (Fig. 4.4). This indicates that metal binding at this site is not required for 
the interaction of S100A9 with TLR4. Further, this provides evidence that this zinc-
dependent coordination of the C-terminal tail of S100A9 is not required for the 
interaction with TLR4 and that while the tail may occupy conformations that obstruct 
access to the hydrophobic surface in the absence of zinc, this is not restrictive for 
activation of TLR4. Finally, given the loss of zinc-dependent aggregation in this mutant, 
this indicates that aggregation does not appear to be the mechanism for zinc-regulation of 
the interaction with S100A9.  
 
Activation of TLR4 by S100A9 occurs in the absence of zinc binding 
Retention of activation of TLR4 by the full metal binding site deletion mutant was 
surprising given previous data suggests that zinc regulates the interaction with TLR468. 
We wanted to validate that we had disrupted zinc binding under cell culture treatment 
conditions in this mutant and that activation of TLR4 was not dependent on the 
concentration of zinc in treatment conditions.  
To validate that S100A9 binds to transition metals in TLR4 activation 
experiments and to confirm that we had disrupted zinc binding in the metal mutant, we 




performed activation experiments in 25% buffer (20 mM HEPES, 100 mM NaCl, pH 7.4) 
and 75% media (Dulbecco's Modified Eagle Medium (DMEM) + 10% fetal bovine serum 
(FBS)). We prepared treatments as for the HEK cell culture assay and incubated these for 
1 hour at 37oC with 5% CO2. We used 3K filtration devices to separate protein from 
media. Using ICP-MS we determined the concentration of zinc in the filtrate (Table 
AC2). We compared the zinc concentration of untreated samples to samples treated with 
2 µM protein. S100A9, S100A9∆99, and S100A9(C3S) all show depletion of zinc from 
the media with respect to untreated sample, while S100A9∆Zn contains the same 
concentration of zinc as untreated (Fig. 4.5A). This indicates that wild-type protein is 
binding zinc under cell culture treatment conditions and that we have disrupted zinc 
binding in our metal site deletion mutant. 
 
Figure 4.5. S100A9 activation of TLR4 does not require zinc binding. A) S100A9 
binds to and depletes zinc from cell culture media. Zinc binding is disrupted for 
S100A9(ΔZn). Y-axis is calculated as % of zinc remaining as compared to untreated 
sample. Second y-axis shows average concentration of zinc detected in each sample. 
Error bars are standard deviation of two replicates. B) Activation of TLR4 by S100A9 
in high and low zinc conditions. We tested activation by different concentrations of 
S100A9 in the presence and absence of 10% FBS which contributes zinc to the media. 
Points are technical triplicates from three biological replicates. Error bars show a 





In earlier studies, we measured activation of TLR4 by S100A9 in media without 
FBS90. DMEM is a defined medium which does not contain any added zinc but has been 
shown to contain nanomolar levels of free zinc. We posited that there may not be 
sufficient zinc in the DMEM alone for S100A9 to be zinc-loaded. To ensure that there 
was sufficient zinc present within our experiments presented here, we chose to test 
activation with 75% DMEM + 10% FBS. The zinc concentration of DMEM + 10% FBS 
has been measured to be in the micromolar range. To determine if this difference in zinc 
concentration altered activation of TLR4 by S100A9, we compared activation of TLR4 
by wild-type S100A9 in low zinc conditions (DMEM) and under conditions with high 
concentrations of zinc (DMEM with 10% FBS). We observed no change in the ability of 
S100A9 to activate TLR4 under these conditions (Fig. 4.5B). These results demonstrate 
that there is no difference in activation of TLR4 under high or low zinc conditions.  
 
DISCUSSION 
We find that zinc-binding involves many residues in S100A9. We show that there 
are two distinct processes for zinc-binding, one of which involves the C-terminal tail and 
the other does not. Additionally, we find that mutagenesis of the residues which 
participate in zinc binding by S100A9 in the heterodimer fully ablate metal binding by 
S100A9.  
We also demonstrate that zinc is not required for activation of TLR4 by S100A9. 
Deletion of the transition metal binding site on S100A9 alters the ability of the protein to 
bind zinc under cell culture treatment conditions but does not alter the ability of S100A9 




given that it is contrary to previous studies which showed zinc-regulation of S100A9 
binding to TLR4 in vitro68. However, our results here strongly suggest that the cell 
culture assay is measuring zinc-independent activation of TLR4 by S100A9.  
 Zinc-independent activation of TLR4 by S100A9 means that pro-inflammatory 
activity is separate from antibacterial activity of the protein. As part of the heterocomplex 
calprotectin, S100A9 is a potent antimicrobial protein through high-affinity metal 
chelation65,171–173. Our results here suggest that metal binding and therefore this nutrient 
sequestration-based antimicrobial activity is functionally separable from pro-
inflammatory activity. The functional separation of these activities on S100A9 provides a 
means to piece apart the effect of these two functions of S100A9 during disease. One 
challenge in assessing the impact of S100A9 inhibition in hosts to limit inflammatory 
response, is predicting the overall effect of inhibition of S100A9’s additional protective 
functions for the innate immune system. The antimicrobial activity of S100A9 may play a 
role in inhibiting proinflammatory response in hosts by controlling the spread of infection 
through nutrient sequestration. 
We also show that the C-terminal tail of S100A9 is not required for the interaction 
with TLR4. Many biological functions both within cells and outside cells have been 
attributed to the flexible C-terminal tail of S100A9. The C-terminal peptide inhibits 
macrophage spreading and phagocytosis of adherent peritoneal lavage cells178,179. It is 
also directly involved in arachidonic acid binding and activation of oxidative burst180. 
The lack of involvement of the C-terminal in pro-inflammatory activity suggests that 
these functions, like antimicrobial activity, are functionally separable from TLR4-




one possibility is that in the C-terminal tail may be cleaved and functioning 
independently of S100A9. If the C-terminal tail is cleaved from S100A9 in the 
extracellular space, the independence of extracellular functions for the tail could be 
important for retention of pro-inflammatory activity post-cleavage.  
Our results here suggest that the zinc-dependent aggregation is not required for 
activation by S100A9. Concentrations of zinc in the extracellular space are sufficient to 
induce aggregation of S100A9 in vitro, and these aggregates have been observed in 
hosts170,176. Understanding whether the aggregate was the active potently pro-
inflammatory form of S100A9 or a built-in dampening mechanism for pro-inflammatory 
activity is an important step in understanding the pathology of S100A9. Further work is 
needed to address whether the zinc-induced aggregation results in a loss in pro-
inflammatory activity. If so, Zn2+-induced aggregation of S100A9 may not only be a 
mechanism for controlling the pro-inflammatory activity but also provide a pathway for 
sinking transition metals into abscesses. The heterodimer of S100A9/S100A8 has been 
found to be a large component of metal-protein abscesses found in infected tissue181. 
Aggregation could serve the dual-function by providing an initial pro-inflammatory 
response to control the spread of an infection and continuing to play a role in controlling 
the spread of infection through nutrient sequestration following aggregation.  
Our experiments provide evidence of metal-independent activation of TLR4 by 
S100A9. Further work is needed to address the effect of additional perturbations to 
S100A9 on target binding interactions in vitro. Zinc-aggregation of S100A9 has 
previously been a technical challenge in these types of analyses, however, our 




done in the absence of zinc. Finally, this work demonstrates that antimicrobial activity 
and arachidonic acid binding activity are functionally separate on S100A9 from pro-
inflammatory activity, providing a future means to examine the independent roles of 
S100A9 in innate immune response.  
 
MATERIALS & METHODS 
Plasmids and recombinant protein preparation and characterization  
Mammalian expression vectors were obtained from Addgene. The construct 
containing human TLR4 was made available by Ruslan Medzhitov (Addgene plasmid 
#13085). Constructs containing human CD14 and ELAM-Luc were obtained from Doug 
Golenbock (Addgene plasmid #13645 and #13029). Human MD-2 was obtained from the 
DNASU Repository (HsCD00439889).  
A synthetic gene construct for human S100A9 (UniProt #P06702) was designed 
to be free of common restriction sites and codon optimized and purchased as PUC57 
construct from Genscript (New Jersey, USA). S100A9 were cloned into a modified 6xHis 
MBP LIC TEV vector with NcoI and HindIII to yield a protein constructs with a TEV-
cleavable histidine tag. Mutations to S100A9 were made using the QuikChange 
Lightning Mutagenesis Kit from Agilent Technologies (Santa Clara, CA). 
To express S100A9 wild-type and mutants, E. coli BL21(DE3) pLysS competent 
cells containing the expression vectors for S100 proteins were grown overnight at 37oC, 
diluted 1:150 into LB containing ampicillin and chloramphenicol, grown to mid-log 
phase (OD600 ~ 0.6-1), and induced with 1 mM isopropyl-β-d-1-thiogalactopyranoside 




3000 rpm at 4o C for 20 min and stored at -20o C. Pellets (~5 g) were suspended by 
vortexing and lysed in 25 mL Buffer (25 mM Tris, 100 mM NaCl, 25 mM imidazole, pH 
7.4) with 37.5 U DNase I (ThermoFisher Scientific) and 0.75 mg Lysozyme 
(ThermoFisher Scientific) by shaking at RT for approximately 1 hr. The lysate was 
clarified by centrifugation at 15,000 RPM for 50 min. at 4o C. Protein was purified using 
a 5 mL Ni2+-NTA HisTrap column from (Healthcare GE) using an FPLC (Akta 
Biosciences) with gradient elution to HisB (25 mM Tris, 100 mM NaCl, pH 7.4, with 500 
mM imidazole for human, mouse and chicken proteins, 1 M imidazole for opossum 
S100A9). Pooled elution peak of purified protein was cleaved with tobacco etch protease 
(TEV) overnight at RT. Cleaved protein was collected from a gradient elution of a 5 mL 
Ni-NTA column from HisA to HisB. Protein purity was assessed with SDS-PAGE and 
pure fractions were pooled and dialyzed into 20 mM HEPES, 100 mM NaCl, pH 7.4, 
treated with 10g/L chelex. For proteins containing cysteine (wild-type and S100A9∆99, 
0.5 mM TCEP was included in dialysis. Protein was flash frozen in liquid nitrogen and 
fresh aliquots were thawed and exchanged into fresh 20 mM HEPES, 100 mM NaCl, pH 
7 (prepared with endotoxin-free water) with 3K Nanosep centrifugal devices prior to 
functional assays. While results shown here are replicates from a single protein prep, 
TLR4 activation was tested with two independent preps of each mutant to ensure that the 
results were not batch specific. Protein concentrations were measured using a Bradford 
assay.  
For metal binding experiments, protein was exchanged into 20 mM HEPES, 100 
mM NaCl, 500 µM TCEP, 200 µM CaCl2, pH 7.4 and concentration was measured with a 




titrations were performed all on the same day, with the same titrant (500 µM ZnCl2, 20 
mM HEPES, 100 mM NaCl, 500 µM TCEP, 200 µM CaCl2, pH 7.4) in an ITC200 from 
MicroCal. Injections were 2 uL. Integrations were performed with Microcal Software.  
For secondary structure measurements, protein samples were prepared at 20 µM 
in 10 mM Trizma, pH 7. Far-UV circular dichroism data was collected between 200–250 
nm using a J-815 CD spectrometer (Jasco) with a 1 mm quartz spectrophotometer cell 
(Starna Cells, Inc. Catalog No. 1-Q-1). Assays for zinc-dependent aggregation were 
performed by adding 100 µM CaCl2, then 100 µM ZnCl2, and finally 500 µM EDTA. 
Aggregation was tested in duplicate for each protein. Raw ellipticity was converted into 
mean molar ellipticity using concentration and the number of residues for each protein. 
 
Cell culture and transfection conditions 
Human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in DMEM supplemented with 10% FBS at 37o C with 5% 
CO2. For each transfection, a confluent 100 mm plate of HEK293T/17 cells was treated at 
room temperature with 0.25% Trypsin-EDTA in HBSS and resuspended with an addition 
of DMEM + 10% FBS. This was diluted 4-fold into fresh medium and 135 µL aliquots of 
resuspended cells were transferred to a 96-well cell culture treated plate. Transfection 
mixes were made with 10 ng of TLR4, 1 ng of CD14, 0.5 ng of MD-2, 0.1 ng of Renilla, 
20 ng of ELAM-Luc, and 68.4 ng pcDNA3.1(+) per well for a total of 100 ng of DNA, 
diluted in OptiMEM to a volume of 10 µL/well. To the DNA mix, 0.5 µL per well of 
PLUS reagent was added followed by a brief vortex and RT incubation for 10 min. 




DNA + PLUS mix, vortexed briefly and incubated at RT for 15 min. The transfection 
mix was diluted to 65 µL/well in OptiMEM and aliquoted onto a plate. Cells were 
incubated with transfection mix overnight (18-22 hrs) and then treated with protein (0-10 
µM) or LPS (100 ng/well) mixtures prepared in 25% buffer (20 mM HEPES, 100 mM 
NaCl, pH 7.4) and 75% cell culture media (DMEM + 10% FBS). E. coli K-12 LPS (tlrl-
eklps, Invivogen) was dissolved at 5 mg/mL in endotoxin free water, aliquots were stored 
at -20o C. To avoid freeze-thaw cycles, working stocks of LPS were prepared at 10 ug/mL 
and stored at 4o C. There has been some concern in testing recombinant DAMPs against 
TLR4 due to the potential presence of contaminating LPS in proteins which have been 
expressed in bacteria 7,9. We tested our S100s in the presence of 50 µg/mL polymyxin B, 
an LPS binding agent to limit signaling from LPS contamination in recombinant protein 
preparations. This concentration of polymyxin B eliminated signaling by 100 ng/mL of 
LPS but had a minimal effect on the signaling by S100A9. Cells were incubated with 
treatments for 4 hr. The Dual-Glo Luciferase Assay System (Promega) was used to assay 
Firefly and Renilla luciferase activity of individual wells. Each NF-κB induction value 
shown represents the Firefly luciferase activity/Renilla luciferase activity. 
 
Metal depletion experiments  
Samples were prepared in the same way as HEK cell treatments. First, 150 uL of 
8 uM protein was prepared in chelex treated 20 mM HEPES, 100 mM, pH 7.4, then 
protein was diluted 1:4 into DMEM + 10% FBS. Samples were incubated in cell culture 
incubator (37 C with 5% CO2) for 1 hr and then filtered with 15 mL 3K microsep 




ICP-MS. ICPMS measurements were in the OHSU Elemental Analysis Core with partial 
support from NIH core grant S10RR025512.  
For each sample, 100 µl of the filtered media solution was added to 1 ml of 1 % 
HNO3 (trace metal grade, Fisher) in a 15 ml acid-rinsed centrifuge tube (VWR). The 
final dilution factor was 11 (1100 µl / 100 µl). The concentrations listed in the 
supplement reflect the concentration in the original samples (Table AC2). Inductively 
coupled plasma mass spectroscopy (ICP MS) analysis was performed using an Agilent 
7700x equipped with an ASX 500 autosampler. The system was operated at a radio 
frequency power of 1550 W, an argon plasma gas flow rate of 15 L/min, Ar carrier gas 
flow rate of 0.9 L/min. Elements were measured in kinetic energy discrimination (KED) 
mode using He gas (4.3 ml/min). Data were quantified using a 11-point (0, 0.5, 1, 2, 5, 
10, 20, 50, 100, 500, 1000 ppb (ng/g) for Ca, Mn, Fe, Cu, and Zn using a multi-element 
standard. For each sample, data were acquired in triplicates and averaged. A coefficient 
of variance (CoV) was determined from frequent measurements of a sample containing 
~10 ppb of Mn, Fe, Cu, and Zn. An internal standard (Sc, Ge, Bi) continuously 
introduced with the sample was used to correct for detector fluctuations and to monitor 
plasma stability. Elemental recovery was evaluated by measuring NIST reference 
material (water, SRM 1643f) and found to within 90 - 100% for all determined elements. 
 
BRIDGE TO CHAPTER V 
 In this chapter, we described how we characterized zinc binding to S100A9 and 
determined that zinc binding is not required for activation of TLR4. We showed that 




S100 transition metal binding site and that disruption of this site does not alter TLR4 
activation. We also demonstrate that the C-terminal tail of S100A9 is not required for 
TLR4 activation. This chapter employed traditional biochemical and functional assays to 
determine the role of zinc in S100A9 activation of TLR4. In Chapter V, we show how 
incorporating an evolutionary perspective in studies of S100A9, TLR4, MD-2, and CD14 






PHYLOGENETIC ANALYSIS LEADS TO MECHANISTIC HYPOTHESES 
REGARDING MECHANISM OF TLR4 ACTIVATION BY LIPOPOLYSACCHARIDE 
AND CALGRANULINS 
 
This chapter contains co-authored material. Phylogenetic analysis and ancestral state 
reconstruction were performed by me. Experimental work was performed by me, J.L 
Harman, and G.L. Waddell. Figures were constructed by me and J.L. Harman. This 
excerpt was written by me, with portions of the methods section contributed by J.L. 
Harman and editorial assistance from Michael J. Harms. 
 
INTRODUCTION 
Evolutionary biology and biochemistry each offer unique insights into the 
diversity and complexity of biological systems. Employing these two perspectives 
simultaneously provides great advantages for understanding the how and the why in 
biology182. 
Early evolutionary biology was done exclusively at the organismal level. Initially, 
the potential value of molecular insights to evolutionary studies was largely ignored and 
even in some cases disputed183,184. However, by the early 1960s, the potential use of 
evolutionary theory to gain insight into molecular questions was gaining popularity. In 
1961, Mayr argued that while “how” questions might be addressed with molecular 




biological phenomenon occurs, historical context is essential. Dobzhansky’s famous 
quote, “Nothing in biology makes sense, except in light of evolution” also reflects this 
sentiment –mechanistic studies of biological molecules at the chemical and physical level 
are expanded by consideration of the evolutionary processes which drove their 
development 186.  
Three primary paleomolecular methods are used to gain evolutionary insight into 
protein function: phylogenetics, ancestral state reconstruction (ASR), and co-evolutionary 
analysis81. Phylogenetics reveals the evolutionary relationship between extant proteins. 
Understanding the distribution of function across a phylogenetic tree leads to hypotheses 
for the timeline in which a new function arose. When coupled with sequence data, 
knowledge of the historical interval in which a function evolved can lead to mechanistic 
insight into how that function evolved81. ASR uses a phylogenetic tree and a multiple 
sequence alignment to infer the sequence of a protein at an ancestral node. Using 
ancestral state reconstruction, it is possible to elucidate the specific set of amino acid 
changes which occurred along a given interval and to reintroduce the minimal set of 
sequence changes into the appropriate historical background. These methods in 
combination permit one to retrace the historical steps that built a function onto a 
historical protein framework. This is different from traditional biochemical methods 
which identify important molecular components of a function by attempting to break that 
function in an extant protein. Finally, co-evolutionary analysis tests whether members of 
a protein complex are compatible with proteins from different organisms. This method 
can be used to determine if a function that is shared across a clade is mediated by a 




Over the past few decades, the use of these approaches has expanded, leading to 
mechanistic insights into protein evolution for a diversity of protein families76–80,187. 
Further, the generation of ancient proteins has allowed us to experimentally test 
hypotheses regarding ancient protein features and trends, such as stability and 
promiscuity188–191. Here we demonstrate the power of an evolutionary approach to 
biochemistry for the proteins addressed in this thesis: calgranulins, TLR4, MD-2, and 
CD14. The goal of this chapter is to convey the diversity of insight one gains from 
including an evolutionary perspective for biochemical studies, using different members 
of the complex as case studies. 
 
POLARIZE TRANSITIONS WITHIN A PROTEIN FAMILY 
 From examination of modern proteins, it is not always clear when a transition of 
interest occurred. Defining the directionality of evolution of a function can reveal which 
function is “special” within a clade. For example, S100A8 and S100A9 form a 
heterocomplex calprotectin (CP) that is protease-resistant192. In contrast, homodimers of 
S100A8 and S100A9 are readily degraded by proteases193,194. Work has focused on 
determining the molecular basis for protease resistance of the heterodimer192; however, it 
could be that resistance is ancestral, and that rather than a gain of protease resistance in 
the heterodimer, the homodimers lost this feature. Distinguishing between these 
possibilities could allow us to identify the key mutations that are responsible for 





Ancestral state reconstruction of calgranulins reveals historical substitution important 
for proteolytic susceptibility of S100A9 
In vivo, S100A9 is predominantly observed as a heterodimer. We hypothesized 
that homodimer degradation is the mechanism by which CP is selectively enriched in 
vivo. Looking at modern proteins, it is not clear whether a transition occurred from 
susceptible to resistant or resistant to susceptible? Phylogenetics and ASR provided a 
means to answer this question. 
We set out to determine if proteolytic resistance was specific to the 
S100A8/S100A9 heterodimer or if S100s in general exhibit protease resistance. To 
distinguish between these possibilities, we tested the proteolytic susceptibility of S100 
proteins across the phylogenetic tree. We chose to use proteinase K to test protease 
resistance as it is a robust protease which has previously been shown to degrade S100A8 
and S100A9 homodimers but not CP. Additionally, proteinase K is a serine protease, 
mimicking neutrophil serine proteasses (NSPs) that get released at sites of inflammation. 
We observed that other S100s outside of the calgranulin clade of S100 proteins do exhibit 
resistance to degradation by proteinase K (Fig. 5.1). Further, S100A12 and MRP-126 
exhibit protease resistance (Fig. 5.1). This indicates that proteolytic susceptibility appears 
to have evolved along the S100A8 and S100A9 lineages from a protease-resistant 
ancestor. 
To determine when within the mammalian S100A8 and S100A9 lineages protease 
susceptibility evolved, we examined protease resistance of a marsupial S100A8 and 
S100A9. We chose to use opossum S100A8 and S100A9 proteins for this purpose. 




these extant proteins, like human S100A8 and S100A9, are susceptible to proteinase K 
(Fig. 5.1). This indicates that protease susceptibility of S100A8 and S100A9 appears to 
be shared across mammalian S100A8s and S100A9s. This suggests that the therian 
mammal ancestor of S100A8 and the therian mammal ancestor of S100A9 should also 
exhibit protease susceptibility. Direct measurement of protease susceptibility of these 
ancestral sequences would reveal if this activity evolved between amniote ancestor and 
the ancestor of therian mammals. 
 
 
Figure 5.1. Human A8 and A9 homodimers uniquely lost proteolytic resistance in 
the S100s. A sampling of S100 proteolytic susceptibility across the phylogeny. Y-axis 
represents the percentage of the detectable protein remaining after 30 minutes of 
treatment with proteinase K. Bars represent average from multiple replicates. Error 
bars show standard error. Amniote A8s and A9s are readily degraded, while CPs are 
protease-resistant. Human A12 and chicken MRP126 are more resistant than A8 or A9 
homodimers. 3 out of 7 non-calgranulin S100s tested were protease-resistant, while 
two exhibited intermediate resistance and two were rapidly degraded.  
 
S100A8 and S100A9 evolved from a protease-resistant ancestor 
To test the hypothesis that S100A8 and S100A9 evolved from a protease-resistant 




calgranulin protein. One challenge in reconstructing the ancestor of S100A8 and S100A9 
is that the exact topology within the calgranulin clade of S100 proteins is not able to be 
resolved90. We hypothesized that given that S100A8, S100A9, and S100A12 are all 
mammalian-specific proteins and that MRP-126 is specific to sauropsids that there may 
have been one ancestral calgranulin in early amniotes and that S100A8, S100A9 and 
S100A12 are the result of mammalian-specific gene duplication events.  
There are two sources of uncertainty: topological and low signal at each site in the 
alignment. We investigated controls for both sources of uncertainty. Due to the difficulty 
in assigning a branching pattern within this clade of S100 proteins, we chose to 
reconstruct the sequences for ancestral calgranulins for species-corrected trees for all 15 
potential topologies for the clade containing S100A8, S100A9, S100A12, and MRP-126. 
To address phylogenetic uncertainty, we chose to use an AltAll reconstruction195, which 
contained substitutions to the next most likely residue at all sites where the second most 
likely residue had a posterior probability of >0.25. Examination of the sequences for the 
15 possible reconstructions of ancestral calgranulin revealed that the phylogenetic 
uncertainty in the reconstruction was greater than the uncertainty in reconstructed 
sequences for the various topologies. Therefore, an AltAll reconstruction of the ancestral 
calgranulin tested not only the robustness of the functional measurement to phylogenetic 
uncertainty in the reconstruction but also tested the robustness of this measurement to the 
topological uncertainty in the tree.  
We expressed and purified both the ancestral calgranulin and the AltAll 
reconstruction to determine if these proteins were susceptible to proteinase K 




(altancCG) were protease-resistant (Fig. 5.2). This is consistent with our hypothesis that 
S100A8 and S100A9 evolved from a protease-resistant ancestral state.  
 
Proteolytic susceptibility for S100A8 and S100A9 evolved along mammalian lineages 
Given that all extant mammalian S100A8 and S100A9s that we tested were 
protease susceptible, we hypothesized that the therian ancestor for S100A9 and S100A8 
would also be susceptible to proteases. We therefore also reconstructed the ancestral 
sequences for therian S100A8 and S100A9 for the topology with the highest log-
likelihood topology of the calgranulin clade. We expressed and purified these proteins, 
along with the AltAll reconstructions and tested for degradation by proteinase K. The 
 
Figure 5.2. Proteolysis of ancestral calgranulins and ancestral S100A8 and 
S100A9 reveals proteolytic susceptibility evolved along the mammalian lineages 
for S100A8 and S100A9. Percentage of protein remaining following 30 min digestion 
with proteinase K is shown for the ML ancestral calgranulin (ancCG) and the AltAll 
(altancCG) in yellow. In addition, protease susceptibility for the ML (ancA8, ancA9) 
and the AltAll (altancA8, altancA9) for therian S100A8 (green) and S100A9 (purple). 
Cartoon tree is used to show which ancestors were used in this analysis. Y-axis 
represents the percentage of the detectable protein remaining after 30 minutes of 
treatment with proteinase K. Bars represent average from multiple replicates. Error 




therian S100A8 and S100A9 were resistant to proteinase K, as expected (Fig. 5.2). 
However, the AltAll reconstructions were not resistant to proteinase K (Fig. 5.2). As the 
functional measurement for this ancestral node was not robust to phylogenetic 
uncertainty, we cannot assert that the protease-stability for this ancestral state with 
certainty. However, the difference in function between the ML reconstruction and the 
AltAll does provide a defined set of historical substitutions that occurred between the 
ancestral calgranulin and the extant S100 proteins that are useful for dissecting the 
evolution of protease susceptibility.  
 
A single historical substitution restores protease resistance in human S100A9 
For the therian ancestor of S100A9, there are 17 amino acid differences between 
the ML ancestor and the AltAll, 7 of these differences are in the C-terminal extension 
which is specific to S100A9. All or some subset of these substitutions must be 
responsible for the difference in the protease susceptibility between these two proteins. 
As the ancestral calgranulin and the AltAll calgranulin ancestor are both protease 
resistant, we chose to test only sites that are different between the ML and the AltAll 
ancestor of therian S100A9, but the same in the AltAll as in the calgranulin ancestor. 
This led to the identification of two potential residues that we hypothesized might be 
important for modulating this activity, N60D, and M63F. We mutated these sites and 
therian S100A9 (ancA9) and observed a gain of proteolytic resistance for this protein 
(Fig. 5.3A).  
Next, we set out to test if either of these historical substitutions were able to revert 




M63F as phenylalanine is present at this site in many extant mammalian protease-
resistant S100s. We found that M63F was sufficient to induce protease resistance in 
human S100A9. Interestingly, S100A8 is protease susceptible but contains the ancestral 
phenylalanine at this position. This indicates that S100A8 independently evolved 
protease susceptibility by an alternate mechanism than S100A9.  
 
 
Figure 5.3. A single historical substitution altered protease susceptibility for 
S100A9. A. Introduction of N60D and M63F into ancestral S100A9 leads to protease-
resistance, as observed in altancA9. B. Proteinase K susceptibility of human S100A9 is 
altered with the introduction of M63F. Y-axis represents the percentage of the 
detectable protein remaining after 30 minutes of treatment with proteinase K. Bars 
represent average from multiple replicates. Error bars are used to show standard error 
of measurements. 
 
An evolutionary approach for the calgranulin proteins revealed that proteolytic 
susceptibility is a uniquely derived feature of the homodimers and not specific to the 
heterodimer. The result of this feature biologically is that the predominant form observed 
in hosts is the proteolytic-resistant heterodimer of S100A8 and S100A9, calprotectin. 
This work reveals that proteolytic resistance is not a unique feature of the heterodimer 
within the S100 family but rather that proteolytic resistance is an ancestral trait. We 
identified a single substitution that restores ancestral proteolytic resistance to human 




S100A8 it appears that proteolytic susceptibility evolved independently, by an alternate 
molecular mechanism along the S100A8 lineage.  
 
IDENTIFY HISTORICAL SUBSTITUTIONS IMPORTANT FOR FUNCTION OF 
INTEREST 
Sometimes, it is difficult to identify mutants of interest for a given function. If the 
molecular basis for a trait is not yet understood, it is often difficult to devise a directed 
experimental strategy towards an understanding of how a function works. Often, when 
faced with such a dilemma, one employs high-throughput methods to begin to break apart 
the function, which can often be insufficient, either because the modification has too 
small an effect (single point mutants) or to large an effect (massive deletions) which may 
alter more than just the given function of interest. ASR offers an alternative approach. 
One can focus on simply the set of historical substitutions which resulted in the evolution 
of a function of interest. This can lead to identification of the minimal set of substitutions 
necessary to alter a given function. 
 
Identification of historical substitutions in the ectodomain of Toll-like receptor 4 that 
resulted in inhibition of ligand-independent activation  
The highly conserved endodomain of TLR4 is a constitutive dimer101,196,197. 
Dimerization of the endodomain leads to activation of the NF-kB pro-inflammatory 
pathway198. However, in the absence of ligand, the ectodomain of TLR4 inhibits 
dimerization of the endodomain, thereby serving as a switch for ligand binding and 




We hypothesized that inhibition of constitutive activity by the ectodomain 
increased along the human lineage. Mouse and opossum TLR4 complexes exhibit 
significant constitutive activity in a cell culture assay, while human TLR4 does not200. 
This distribution of function across the phylogenetic tree suggests that changes occurred 
along the human lineage which resulted in an increase in the ability of the ectodomain of 
TLR4 to inhibit ligand-independent dimerization of the endodomain.  
Understanding the underlying molecular basis for inhibition of constitutive 
activity by the ectodomain of TLR4 is important for rational design of inhibitors of 
activation of this protein both in the presence and absence of ligand. Here, we used 
ancestral state reconstruction to identify substitutions which occurred on the human 
lineage, since the ancestor of humans and mice, which are involved in the inhibition of 
ligand-independent activation.  
 
Horizontal mutagenesis for human and mouse TLR4 reveals epistasis 
By testing N-terminal truncation mutants of human TLR4, a previous study found 
that a small segment of the extracellular domain (90 residues) is sufficient to inhibit 
ligand-independent activation of NF-kB cascade196. Examination of this region reveals 
two historical substitutions have occurred on the human lineage at sites where the 
ancestral state has been maintained in opossum and mouse. We hypothesized that these 
residues may be important for inhibiting ligand-independent activation in human TLR4. 
To test the role for these residues in regulating ligand-independent activation, we 
introduced the residues in human TLR4 at these sites into the mouse protein. Introduction 




activation. This indicates that these sites are potentially important for ectodomain 
inhibition of constitutive activity in the human TLR4 (Fig. 5.4). Next, we introduced the 
mouse residues at these sites into human TLR4. These substitutions did not lead to an 
increase in constitutive activity (Fig. 5.4). This indicates that there are likely additional 
substitutions that occurred along this lineage that also regulate this activity. 
 
Figure 5.4. Two sites which changed along the human lineage disrupt constitutive 
activity in the mouse TLR4 A. Alignment of 20-residue region previously shown to 
be important for ectodomain inhibition of constitutive activity for human, mouse, and 
opossum. Two sites are highlighted which changed specifically along the human 
lineage B. Introduction of the ancestral residue at these sites in the full-length and 
truncated flag-tagged human TLR4. Points represent technical triplicates from single 
biological replicate. Error bars are a standard error on the mean. 
 
Inhibition of endodomain constitutive activity evolved on the human lineage 
To test our hypothesis that this inhibition of constitutive activity evolved along 
the human lineage since the ancestor of humans and mice, we performed phylogenetic 
analysis and ancestral state reconstruction for TLR4. We compiled a database of 199 
vertebrate TLR4 sequences using BLAST and created a multiple sequence alignment. 
Next, we constructed a species-corrected maximum-likelihood tree for vertebrate TLR4. 
Ancestral sequences were reconstructed using PAML201, gaps were inferred based on 




This early reconstruction for the ancestor of human and mouse TLR4 contained 
the cysteine found in mouse and opossum in the first site of interest, but a glutamic acid 
in the second position, differing from both the mouse and opossum. The inferred 
sequence for TLR4 from the ancestor of human and mice was synthesized and cloned 
into a mammalian expression vector. We tested this protein for constitutive activation and 
observed that, like the mouse and opossum proteins, the TLR4 present in the ancestor of 
humans and mice was constitutive as well.  
 
Historical substitutions are sufficient to disrupt inhibition of endodomain constitutive 
activity for truncated human TLR4 
We next chose to introduce these changes into an N-terminally truncated human 
TLR4 to test if these substitutions altered inhibition of constitutive activity in a truncation 
mutant containing only the 90-residue region of the ectodomain which is sufficient for 
inhibiting constitutive dimerization of the endodomain. In this truncated protein, these 
reversions increase the constitutive activity of human TLR4 (Fig. 5.5). This suggests a 
historical importance for these substitutions in regulating the constitutive activity of the 
endodomain of TLR4.  
This work is ongoing, I recently repeated the ancestral state reconstruction for 
TLR4 with additional sequence data to confirm the sequence within this region. This 
reconstructed ancestor contains the same residues at both sites of interest as observed in 
the mouse and opossum proteins, with high posterior probability. We plan to assess 
whether this ancestor also displays a level of constitutive activation consistent with that 




glycine at position 561 is sufficient to disrupt the constitutive activity observed in the 
truncated human TLR4. We also plan to test the effect of the human substitutions in 
ancestral TLR4. This will reveal whether these substitutions are sufficient in the ancestral 
state to induce a reduction of constitutive activity. 
 
Figure 5.5. Two historical substitutions which modulate constitutive activity. A. 
Structure of TLR4 with minimal 90-residue region sufficient for inhibition of 
constitutive activity highlighted in green and two residues shown in orange which were 
predicted to modulate this function B. Introduction of the ancestral residue at these 
sites in the full-length and truncated flag-tagged human TLR4. Points represent 
technical triplicates from single biological replicate. Error bars are a standard error on 
the mean.  
 
Inhibition of ligand-independent activation by the ectodomain of TLR4 has been 
observed in the previous studies196, but a hypothesis for the molecular mechanism for this 
trait was missing. Here, using variation in extant species to direct our study, we identified 
two sites which modulate this function. By identifying a minimal mutation set that alters 
this trait in extant TLRs we can now work to identify how inhibition of constitutive 
activity by the ectodomain of TLR4 is mediated. Is there protein partner which binds and 




conformation which prohibits dimerization of TLR4 in the absence of ligand? Future 
work is needed to investigate the mechanism by which these mutations alter this function. 
 
REVEAL MOLECULAR BASIS FOR CONSERVED FUNCTION 
Lineage-specific coevolution can lead to incompatibilities between extant proteins 
from different species. However, even when lineage specific coevolution has occurred, 
the core molecular basis for a function may be conserved. Co-evolution between protein 
partners can obscure the ability to identify what the molecular requirements are for the 
function of the complex. By employing methods which incorporate measurements of co-
evolution within a system, we can disentangle these issues and isolate the core molecular 
mechanism of function. 
 
Two residues are predictive of cross-compatibility between vertebrate TLR4 and MD-2s  
TLR4 activation by LPS has previously been shown, by us and others, to be 
dependent on the presence species-specific co-factors21,91,92,155,200. This is most frequently 
observed for human TLR4 which has limited cross-species compatibility with other 
vertebrate MD-2s23,85,86,111. This lack of cross-specificity across vertebrate TLR4/MD-2 
pairs indicates that lineage-specific co-evolution has occurred between these two proteins 
across the vertebrates. This co-evolution may have arisen, in part, due to the evolution of 
specificity toward different LPS chemotypes from different bacterial species.  
Examination of TLR4/MD-2 pairs across the vertebrates reveals that the co-
evolution between MD-2 and TLR4 is not a general trend across vertebrates but has 




compatible with each other but also with zebrafish TLR4. This indicates that like CD14, 
the molecular mechanism for MD-2 appears to be conserved across the vertebrates.  
 
Figure 5.6. TLR4 co-factors MD-2 and CD14 show significant levels of cross-
reactivity across vertebrates. Subpanels show activation of NF-κB signaling by 
receptor complexes assembled from host (black) and guest (red) proteins. Protein 
names on the left and top of each sub-panel indicate the components included. Letters 
indicate which species components come from human (H), mouse (M), opossum (O), 
or chicken (C). If the cross-species complex activates >2-fold above the buffer control, 
the corresponding box is filled gray. The icon to the top-left of each sub-panel indicates 
graphically which components are being combined. * indicates >2-fold activation 
above buffer control, but low total activation. 
 
We looked for regions of MD-2 and TLR4 which are conserved across vertebrates 
to identify the molecular basis for compatibility of vertebrate MD-2s. We found that the 
interface between the N-terminal region of TLR4 and MD-2 is fully conserved across 
vertebrates (Fig. 5.7). Minimal sequence conservation is observed across vertebrate 
TLR4 and MD-2 sequences outside of this region.  
Notably, despite being essential for LPS signaling, the dimerization interface 
between MD-2 and the C-terminal region of TLR4 is not conserved across species (Fig. 
5.8). Differences within this region may account for the differences in LPS sensitivity 
observed across vertebrates. The composition of this loop is quite similar between mouse 
and human MD-2. This is surprising given the lack of compatibility of human MD-2 with 




residues which are predictive of interaction cross-reactivity across the vertebrates (Fig. 
5.8). These two prolines bracket and potentially structure the loop of MD-2 which 
interacts with the C-terminal region of TLR4. 
 
Figure 5.7 Interface between MD-2 and N-terminus of TLR4 appears to be 
conserved across the vertebrates. Structure of TLR4 (orange)/MD-2 (grey) complex 
(PDB: 3fxi) with residues which are conserved across vertebrates highlighted (blue). 
 
 
Cross-compatibility studies with vertebrate MD-2 and TLR4 reveal that the 
molecular mechanism by which MD-2 functions is conserved across vertebrates. By 
examining substitutions which have occurred along specific lineage which lead to 
incompatibilities we were able to identify two sites which are predictive of cross-
compatibility of MD-2 with vertebrate TLR4s. Testing if introduction of these residues 
into the human protein restores cross-compatibility of human MD-2 with opossum TLR4 
will reveal if these two substitutions lead to species-specificity for TLR4/MD-2 pairs. 
Coevolution between TLR4/MD-2 pairs in vertebrates may have been driven by 
evolution for LPS specificity for different species. Further examination of how 
substitution of these sites in the human protein might lead to changes in species-specific 





Figure 5.8 Dimerization interface between TLR4 and MD-2 important for 
activation by LPS is minimally conserved. A. Structure of TLR4 (orange)/MD-2 
(grey) complex (PDB: 3fxi) with conserved residues highlighted (blue). Loop of MD-2 
essential for dimerization of TLR4/MD-2 complexes and downstream activation is 
circled. B. Sequence of loop of MD-2 highlighted in A shows minimal conservation, 
two residues which are predictive of cross-compatibility of MD-2s across vertebrates 
are highlighted with red arrows. 
 
DETERMINE THE HIERARCHY OF FUNCTIONS FOR A MULTI-
FUNCTIONAL PROTEIN  
Proteins often perform more than one function within a cell202. A given protein 
may have multiple protein partners or multiple protein functions. Understanding which of 
these functions is ancestral and when new functions evolved can reveal the hierarchy of 
functions. Phylogenetics can reveal when a new protein arose. Characterization of early 
branching extant proteins and examination of the functional profile of ancestral states can 
expose the order of evolution of functions for a protein of interest. 
 
CD14 appears to have arose in early tetrapods 
Sensitive recognition of LPS is important for early detection of pathogenic 
bacteria by the innate immune system. CD14 directly binds LPS and delivers it to the 




CD14 has previously only been identified in amniotes91,154,200. However, here we show 
that it likely arose due to a duplication of TLR2 in early tetrapods. 
CD14 has only been identified in amniotes and functional validation of sauropsid 
CD14 functioning similarly to mammalian CD14 is recent91,200. However, given our 
recent identification of a MD-2 in amphibians and fish, we revisited the question of when 
CD14 evolved. We identified a putative sequence for an amphibian CD14 annotated in 
the Xenopus genome. Using this sequence, we were able to identify additional amphibian 
CD14 molecules, but were not able unable to find a CD14 in fish, blasting with this 
sequence only revealed TLR2. 
 
Duplication event resulting in CD14 appears to have occurred in early tetrapods 
 TLR2 and CD14 are sister clades (Fig. 5.9A). We reasoned that our inability to 
identify a CD14 in fish could be due to three alternative possibilities – 1. Fish lost CD14, 
2. CD14 exists in fish but has significantly diverged and we are unable to identify it with 
a simple BLAST approach, 3. The duplication event that resulted in CD14 happened after 
the divergence of fish. To distinguish between these possibilities, we set out to determine 
when the duplication event occurred that resulted in CD14.  
First, we constructed a database of TLR2 and CD14 proteins from chordates and 
constructed a maximum likelihood phylogeny, using the JTT model (Fig. 5.9B). The 
phylogeny for TLR2 and CD14 supports the hypothesis of a duplication event occurring 
after the divergence of fish. This is consistent with a model of a single TLR2 being 
present in sharks and fish with a duplication event occurring prior to the divergence of 






Difference in membrane linkage between mammalian and sauropsid CD14 is due to 
serial truncation of the endodomain 
The phylogeny for TLR2 and CD14 reveals significant divergence along the 
amphibian CD14 lineage (Fig. 5.9B). Previously, it has been shown that the membrane 
linkage mechanism for mammalian and sauropsid CD14 is different. Chicken CD14 is a 
transmembrane protein while mammalian CD14s are GPI-coupled to the membrane92. 
Examination of the multiple sequence alignment reveals that this difference in membrane 
linkage is likely due to serial truncations of the internal TIR domain of TLR2 in the 
evolution of tetrapod CD14 (Fig. 5.10). Amphibian and sauropsid CD14 contain a C-
terminal domain which aligns to a significant portion of the TIR domain of TLR2 while 




Figure 5.9. Phylogenetic analysis for CD14. A. Phylogeny for the TLR family. 
Phylogeny was constructed with all known TLRs from human, mouse, opossum, 
chicken, frog, and zebrafish. B. Phylogeny for vertebrate TLR2 and CD14. Phylogeny 





Figure 5.10. Alignment of TLR2 and CD14 from representative vertebrate 
species. Alignment was constructed for sequences from human, opossum, chicken, 
frog and zebrafish CD14 and TLR2. T-Coffee was used to present a structural 
alignment, gap in N-terminal region of CD14 was manually edited to reflect structural 
conservation of the N-terminal domain of TLR2 and CD14.  
 
Pattern for sequence conservation in CD14 suggests ancient role in LPS-sensing 
We have previously observed high cross-specificity of CD14s across the 
amniotes200. This is surprising given how much divergence has occurred along the 
mammalian lineage, as evidenced by the long-branch length for mammalian CD14s since 
the amniote ancestor. We tested whether the high level of divergence observed in the 
phylogeny was due to differences in the membrane linkage by constructing a phylogeny 
with just the ectodomain of CD14. We again observed long-branch lengths indicative of 
significant divergence since the amniote ancestor in the ectodomain (data not shown). 
Examination of conservation of surface residues across vertebrate CD14s reveals 
minimal conservation across the structure. We highlighted residues with greater than 80% 
conservation across the tetrapod CD14s and found that the largest region of conservation 
on the protein surface was in the negative patch in the concave surface of the C-terminal 




to be important for formation of a transient complex with the basic patch of LBP and 
stimulation of NF-kB signaling203. Conservation of this region of CD14 across the 
vertebrates seems to suggest and early role for CD14 in LPS sensing.  
 
 
Figure 5.11. Minimal sequence conservation is observed across tetrapod CD14s. 
CD14 (PDB: 4glp)28 is shown in orange, residues that are conserved across at least 
80% of vertebrate CD14s are shown in blue.  
 
TLR4 has previously been shown to be expressed in frogs204, suggesting that LPS 
recognition in frogs may be occurring via this complex. We tested LPS recognition by the 
full complex of TLR4, MD-2, and CD14 from Xenopus laevis but did not observe 
activation of the full complex in an ex vivo cell culture assay. Given that we have 
previously observed some cross-specificity for individual components of the complex 
across vertebrates, we also examined whether any of the individual components, in 
combination with chicken TLR4, MD-2, and or CD14 could activate with LPS, we did 
not observe activation with Xenopus TLR4 or MD-2 in the presence of chicken complex 
components. We hypothesized that this could be due to a large amount of divergence 
within the signal peptide of frog TLR4. Further work is needed to assess whether use of a 
mammalian signal peptide on this receptor could lead to observations of activation within 




of the chicken TLR4/MD-2 complex with the addition of Xenopus CD14 (Fig. 5.12). 
Additional work is needed to validate the ability of Xenopus CD14 to complement 
additional TLR4/MD-2 complexes to validate functionality of this complex.  
 
 
Figure 5.12. Frog CD14 increases LPS recognition by chicken TLR4/MD-2 
complex. Preliminary analysis of LPS delivery by Xenopus CD14. LPS activation of 
chicken TLR4/MD-2 complex was assessed in the presence and absence of frog CD14. 
Points represent technical triplicate. Error bars are standard error with dash to represent 
mean for replicate.  
 
In mammals, CD14 has been shown to have multiple functions in addition to its 
participation in LPS response205. One of these includes supporting peptidoglycan 
recognition by TLR2206, which we hypothesis, given the shared binding motif for 
peptidoglycan between TLR2 and CD14 is likely the ancestral function of the molecule. 
Cross-reactivity has been observed across the amniotes for lipoprotein delivery by CD14, 
human CD14 can supports lipoprotein recognition by chicken TLR2207. This suggests that 
this role may not only be ancestral, but function via a conserved molecular mechanism. 
Further work may address which functions are ancestral to tetrapod CD14 and when LPS 




 Finally, phylogenetic analysis revealed that CD14 may be tetrapod-specific. This 
is an important finding given the interest in presence of TLR4 co-factors outside of 
amniotes. Here we identify an amphibian CD14. We also show that the difference in 
membrane linkage between chicken and human CD14 is likely due to endodomain 
shortening along the mammalian lineage. This difference in membrane linkage may be 
important for generation of soluble CD14 which has been observed in mammals. Further 
work is needed to examine how this difference in membrane linkage affects function of 
CD14 between mammals and other tetrapods. Patterns of conservation in CD14 across 
tetrapods suggests that the role for LPS-sensing may be an ancient function of CD14. 




Phylogenetics, ancestral state reconstruction, and co-evolutionary analysis are 
powerful approaches for studying biochemistry. Several different types of hypotheses 
were generated by applying these approaches to proteins within an innate immune 
pathway. We identified when important transitions occurred within protein families and 
the minimal historical substitutions needed to reproduce it in an ancestral background. In 
addition, we generated a testable hypothesis for the molecular basis of coevolution for a 
conserved protein complex. Finally, we showed how phylogenetic analysis can lead to 
identification of the hierarchy of functions for multi-functional protein.  
This work highlights several insights for how proteins function and evolve. We 




complex protein features can evolve rapidly with a small number of substitutions. We 
demonstrate that lack of cross-compatibility is not a good indicator of lack of function. 
Further, we show that identifying where lineage-specific coevolution has occurred can 
lead to insights into the molecular determinants of lack of cross-specificity and facilitate 
the parsing of co-evolutionary signal to reveal the core molecular determinants of 
function. Finally, we show how phylogenetic analysis can aid in identification of the 
early features of a multi-functional protein. 
Homology is often used as an indicator of conserved functionality between 
species. Within the rapidly evolving immune system, conservation of function at the 
organismal level may not be indicative of conservation of molecular mechanism. 
Understanding how the molecular details of functions differ between species is essential 
when considering use of animal models for human disease. Coevolution between 
components of the TLR4/MD-2/CD14 complex have already led to challenges in 
identification and validation of antagonists of TLR427,85,86,89,111. The methods described 
here provide a path towards identifying the conserved molecular details and mechanisms 
of activation, but also illuminating the molecular basis for species-specificity. These 
methods may also be applied towards other innate immune receptors, and may prove a 
powerful strategy towards disentangling differences between species in recognition of 
innate immune molecules.  
These examples demonstrate the extraordinary power of considering evolutionary 
history in generating molecular hypotheses for protein function. Phylogenetics and 
ancestral state reconstruction led us to testable hypotheses for all four proteins addressed 




protein functions and examining the distribution of these functions across a phylogenetic 
tree we were able to identify historical substitutions which modulate these functions in 
extant proteins and delineate when new functions arose across within vertebrates.  
 
MATERIALS AND METHODS 
Phylogenetics and ancestral state reconstruction  
For the S100 proteins, we constructed a curated database of homologs from a 
consistent set of species. We obtained amino acids sequences of S100 proteins from a 
subset of the amniote species in Ensembl version_87 159. We obtained additional bird and 
reptile S100A7 and MRP-126 sequences using the human calgranulin paralogs to BLAST 
against the NCBI database. This yielded a set of 172 sequences from 30 taxa (Data Sheet 
S1, S3). We constructed our multiple sequence alignment using MSAPROBS 119, 
followed by manual editing in MEGA 120. We trimmed the alignment to remove highly 
variable (and therefore unalignable) C-terminal extensions, as well as the non-S100 
domains of the fused S100 proteins. We used PHYML 121,122 with subtree pruning and re-
grafting to construct the ML phylogeny. Pilot analyses revealed that the LG substitution 
model with 8 rate categories and a floating gamma distribution parameter yielded the 
highest likelihood trees 123–125. An AIC test was used to control for overfitting 126. We 
rooted our trees using the divergence of S100B, an ancient S100 found across jawed 
vertebrates. This allowed us to determine topology for the calgranulin clade with respect 
to S100A7, S100A15 and fused S100s. We species-corrected these clades using 
Archaeopteryx208 according to NCBI taxonomic data209,210, and published phylogenies of 




calgranulin clade using merely phylogenetic analysis. We constructed 15 possible trees 
for all possible topologies of A8, A9, A12, and MRP-126 and used these species 
corrected trees for reconstruction. The species corrected tree with the highest log-
likelihood was used for ancestral state reconstruction of ancestral S100A8, S100A9 and 
ancestral calgranulins (Fig. AD1). 
For TLR4, MD-2 and CD14 we constructed a curated database of protein 
sequences for each protein from an NCBI BLAST. Additional amphibian sequences were 
identified in amphibian transcriptomes available on dryad. We constructed multiple 
sequence alignments for each protein with MSAPROBS119 followed by manual editing in 
MEGA120. Pilot analyses revealed that the JTT substitution model with 8 rate categories 
and a floating gamma distribution parameter yielded the highest likelihood trees121,123–125. 
We species-corrected these trees using Archaeopteryx208 to reflect published vertebrate 
phylogenies209–212. Species-corrected trees are shown in the supplemental information for 
TLR4 (Fig. AD2), MD-2 (Fig. AD3), and CD14 (Fig. AD4). 
To reconstruct ancestors, we used PAML201,213. We assigned gaps manually using 
parsimony. We generated the AltAll sequences for the therian ancestral S100A8 and  
S100A9 as well as the ancestral amniote calgranulin as described in Eick et al195. This 
incorporates uncertainty in the reconstruction by taking the next-best reconstruction at all 
ambiguous sites. We took each site at which the posterior probability of the next-best 
reconstruction was greater than 0.25 and the introduced that alternate reconstruction at 
the site of interest. These constructs were used in functional assays to assess if the 





Protein expression and purification 
All S100 genes in this study were purchased as synthetic constructs in pUC57 
vectors from Genscript. Calgranulin S100 genes (A8s, A9s, A12s, MRP126s, and 
ancestrally reconstructed genes) were sub-cloned into a pETDuet-1 (pD) vector 
(Millipore). A8s, A12s, MRP126s, and ancCGs were cloned into multiple cloning site #1 
(MCS1) of a pD vector, while A9s were cloned into MCS2. For expression and 
purification of A8/A9 heterocomplexes (CPs), pD plasmids containing an A8 gene in 
MCS1 and an A9 gene in MCS2 were used2. Marsupial A8s (opossum and the 
Tasmanian devil) were sub-cloned into an MBP-LIC vector to yield a His-MBP-TEV-A8 
construct. For marsupial CPs, the entire His-MBP-TEV-A8 gene was then sub-cloned 
into MCS1 of a pD vector containing a marsupial A9 in MCS2. Non-calgranulin S100s 
(A1, A5, A7, A11, A14, P, and tunB) were previously cloned into a pET28/30 vector to 
yield a TEV-cleavable N-terminal His tag3. For cell culture assays, human codon-
optimized S100 genes were sub-cloned into a pCDNA3 vector (Invitrogen). Finally, 
cysteine-free versions of all calgranulin genes, as well as point mutants, were prepared 
using site-directed mutagenesis (Agilent). 
Recombinant proteins were expressed in E. coli BL21(DE3) pLysS Rosetta cells. 
Cultures were inoculated in Luria broth overnight at 37°C, shaking at 250 rpm, in the 
presence of ampicillin and chloramphenicol. The following day, 10 ml of saturated 
culture was diluted into 1.5 L of media with antibiotics, grown to OD600 = 0.6-1, and then 
induced overnight at 16°C using 1 mM IPTG + 7.5 ml of 40% glucose. Cells were 




Lysates were prepared by vortexing pellets (3-5 g) in Tris buffer (25 mM Tris, 
100 mM NaCl, pH 7.4) and incubating for 20 min at RT with DNAse I and lysozyme 
(ThermoFisher Scientific). Lysates were sonicated, and cell debris was pelleted by 
centrifugation at 15,000 rpm at 4°C for > 20 min. All proteins were purified on an Äkta 
PrimePlus FPLC using various 5 ml HiTrap columns (HisTrap FF (Ni-affinity), Q HP 
(anion exchange), SP FF (cation exchange), and MBPTrap HP (MBP) - GE Health 
Science). All non-calgranulin S100s were purified using a TEV-cleavable His tag 
strategy used by our lab previously200. All calgranulin S100s, with the exception of 
marsupial A8s and CPs, were purified in two steps using Ni-affinity chromatography 
followed by anion exchange chromatography. For Ni-affinity chromatography, proteins 
were eluted over a 50 ml gradient from 25-1000 mM imidazole in Tris buffer. Peak 
elution fractions were pooled and placed in dialysis overnight at 4°C in 4 L of Tris buffer 
(calcium-free) adjusted to pH 8. Anion exchange chromatography was then performed 
the following day over a 50 ml gradient from 100-1000 mM NaCl in pH 8 Tris buffer. 
Fractions containing majority S100 were pooled and analyzed for purity on an SDS-
PAGE gel. If trace contaminants remained, an additional cation exchange step was 
performed at pH 6 using the same elution strategy as for anion exchange. 
Marsupial A8 and CP lysates were prepared as above and then flowed over a His 
column, eluting over a 25 ml gradient from 25-1000 mM imidazole in Tris buffer. Peak 
elution was pooled and the MBP tag was cleaved by incubation with ~1:5 TEV protease 
at 4°C overnight in 4 L of Tris buffer + 1 mM EDTA. The MBP tag was then removed 
using amylose affinity chromatography in Tris buffer + 1mM EDTA, eluting stepwise 




+ 2 g/L Chelex-100 resin (BioRad), flash-frozen the following day in liquid nitrogen, and 
stored at -80°C. 
 
Protease susceptibility assays 
For all experiments, protein aliquots were thawed fresh from freezer stocks and 
dialyzed in the appropriate experimental buffer overnight at 4°C. Thawed aliquots were 
used for no more than several days (< 1 week) before discarding. All concentrations were 
measured by Bradford assay and correspond to uM dimeric protein. For in vitro 
proteolytic susceptibility experiments, proteins were exchanged into Tris buffer + 1 mM 
CaCl2. 12.5 uM dimeric S100 protein was treated with 5 uM Proteinase K from 
Tritirachium album (Sigma Aldrich) in thin-walled PCR tubes, which were held at a 
constant temperature of 25°C over the course of the experiment using a thermal cycler. 
Proteinase K activity was quenched at different time points by directly pipetting an 
aliquot of the reaction into an equal volume of 95% Laemmli SDS-PAGE loading buffer 
+ 5% BME at 95°C in a separate thermal cycler. Time points were analyzed via SDS-
PAGE, and gels were quantified using in-house gel analysis software (see GitHub). 
 
Cell culture and transfection conditions 
Human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in DMEM supplemented with 10% FBS at 37o C with 5% 
CO2. For each transfection, a confluent 100 mm plate of HEK293T/17 cells was treated at 
room temperature with 0.25% Trypsin-EDTA in HBSS and re-suspended with an 




aliquots of re-suspended cells were transferred to a 96-well cell culture treated plate. 
Transfection mixes were made with 10 ng of TLR4, 1 ng of CD14, 0.5 ng of MD-2, 0.1 
ng of Renilla, 20 ng of ELAM-Luc, and 68.4 ng pcDNA3.1(+) per well for a total of 100 
ng of DNA, diluted in OptiMEM to a volume of 10 µL/well. Additional TLR4 and MD-2 
was needed for fish and amphibian constructs: 10 ng zebrafish MD-2 was used in 
experiments shown and 10 ng of human, mouse, opossum, and chicken MD-2 was 
therefore used for cross-complementation studies, in addition, to see activation with 
chicken TLR4/MD-2 we needed 10 ng of frog CD14 in transfections. To the DNA mix, 
0.5 µL per well of PLUS reagent was added followed by a brief vortex and RT incubation 
for 10 min. Lipofectamine was diluted 0.5 µL into 9.5 µL OptiMEM per well. This was 
added to the DNA + PLUS mix, vortexed briefly and incubated at RT for 15 min. The 
transfection mix was diluted to 65 µL/well in OptiMEM and aliquoted onto a plate. Cells 
were incubated with transfection mix overnight (18-22 hrs) and then treated with protein 
(2 µM) or LPS (100 ng/well) mixtures (prepared in 25% phosphate buffered saline, 75% 
DMEM). E. coli K-12 LPS (tlrl-eklps, Invivogen) was dissolved at 5 mg/mL in 
endotoxin-free water, aliquots were stored at -20o C. To avoid freeze-thaw cycles, 
working stocks of LPS were prepared at 10 ug/mL and stored at 4o C. Cells were 
incubated with treatments for 4 hrs (or 6 hrs for studies done with zebrafish proteins). 
The Dual-Glo Luciferase Assay System (Promega) was used to assay Firefly and Renilla 
luciferase activity of individual wells. Each NF-κB induction value shown represents the 
Firefly luciferase activity/Renilla luciferase activity, normalized to the LPS-treated 
transfection control for each species in order to normalize between plates. It should be 




species. For constitutive TLR4 experiments, these studies were performed in the absence 
of TLR4 co-factors MD-2 and CD14.  
 
BRIDGE TO CHAPTER VI 
 In this chapter, we showed how an evolutionary perspective has led to testable, 
mechanistic hypotheses for the four protein families described in this thesis. We 
described how the use of phylogenetics, ancestral state reconstruction, and co-
evolutionary analysis can polarize functional transitions within a protein family, lead to 
the identification of residues important for a function of interest, determine the molecular 
mechanism for a conserved function, and determine the hierarchy of functions. In 
Chapter VI, the results from this entire work are summarized and the implications are 













The work presented in this thesis demonstrates the power of using a combination 
of evolutionary and biochemical approaches to learn how complex protein features and 
functions evolve. We determined when two types of agonists, pathogen-derived LPS and 
host-produced S100A9 evolved to activate TLR4. We found that both LPS and S100A9 
activation of TLR4 evolved earlier than previously thought. We describe how we 
identified MD-2 and CD14, essential TLR4 cofactors for both S100A9 and LPS 
signaling, in amphibians and fish. We also show that an ortholog of S100A9 in birds and 
reptiles, MRP-126, is capable of activating TLR4. This work validates new model 
systems for studying human disease. By determining that endogenous activation of TLR4 
occurs out to chickens, we demonstrate that amniote species contain the same 
endogenous positive feedback loop for TLR4 signaling that is observed in humans and 
mice. Further, by validating that zebrafish TLR4 recognizes LPS, we show that Danio 
rerio, a popular model organism for innate immune studies, could be used as a model for 
studying septic shock.  
We also show that S100A9 activation of TLR4 does not require zinc. This means 
that antimicrobial activity, which is accomplished through zinc and manganese 
sequestration by S100s, is functionally separate from pro-inflammatory activity of this 
protein. We also show that the aggregation behavior of S100A9 in the presence of 
transition metals is mediated by metal binding to the canonical S100 transition metal 




reversible, zinc-dependent aggregation behavior of S100A9 is not required for TLR4 
activation. This suggests that zinc-dependent aggregation is not the mechanism by which 
S100A9 signals through TLR4. However, these results do lead to an alternate testable 
hypothesis, that aggregation of S100A9 may be a mechanism for dampening S100A9-
driven pro-inflammatory activity.  
Finally, we show how using co-evolutionary analysis, phylogenetics, and 
ancestral state reconstruction, led to mechanistic hypotheses regarding TLR4 activation 
by both LPS and S100A9. We demonstrate that these techniques can lead to identification 
of mutants that may be difficult to otherwise isolate. We also show how these methods 
can lead to identification of key features that are different between species and therefore 
aid in resolving complications in identification of suitable inhibitors due to difference 
between humans and animal models.  
The hypotheses described here are merely a sampling of those that can be 
generated from phylogenetic data on these proteins. One promising area where these data 
could also be used to build mechanistic hypotheses is in identifying the molecular 
mechanisms of species-specific recognition of various chemotypes of LPS. Others have 
identified that MD-2 plays a role in species specific recognition of LPS molecules and 
have isolated some larger regions of TLR4 which are important for the variance observed 
between extant species85–87,111,214,215. By applying an evolutionary perspective, it may be 
possible to isolate the evolutionary interval within which these specificities arose. 
Further, examination of the profile of LPS recognition by ancestral TLR4s could 





This work forms the basis for a number of ongoing projects in the Harms lab. 
Further characterization of the molecular mechanism by which S100A9 binds to metals 
and to protein targets is ongoing. Additional work is being conducted to identify where 
S100A9 binds to TLR4 and whether the same or different regions of TLR4 are important 
for LPS and S100A9 activation. Finally, further work is being done to understand 
evolution of new functions within these protein families. Overall, the work presented here 
not only gave us insight into the evolution and molecular mechanisms of TLR4 activation 
by LPS and S100A9 but will provide the basis for evolutionary biochemical studies of 






SUPPLEMENTAL MATERIAL FOR CHAPTER II 
 
This section includes the figures and tables referenced in Chapter II. The experimental 





Figure AA1. Alignment of Newly Identified Fish and Amphibian MD-2 Proteins. 
MD-2 proteins were identified using transcriptomic data from amphibians (dryad) and 
fish (Fish1TK). Sequences were aligned with MSAPROBS. Colors are used to denote 






Figure AA2. Alignment of Zebrafish TLR4s with Human TLR4. Sequences were 










Figure AA3. Increasing LPS concentration leads to increasing response of 
zebrafish TLR4a in the presence of zebrafish MD-2 and human CD14, but not 
TLR4b. Points represent average activity detected at each concentration of LPS. Error 
bars are used to show the standard error for three replicates. Points are normalized to 








Figure AA4: Zebrafish TLR4a with MD-2 and TLR2. Activation of zebrafish 
TLR4a with MD-2 in the presence and absence of TLR2 or hCD14. Points are used to 
represent technical triplicates from three biological replicates. Error bars shown are a 






Table AA1: Genome locations for MD-2 proteins shown for synteny analysis. 
Genomic locations were obtained from Ensembl database. 
 
Species Protein Accession  Chromosome Location 
Homo sapiens ELOC ENSG00000154582 8:73939169-73972287 
Homo sapiens TMEM70 ENSG00000175606 8:73972437-73982783 
Homo sapiens LY96 ENSG00000154589 8:73991352-74029087 
Homo sapiens JPH1 ENSG00000104369 8:74234700-74321328 
Homo sapiens GDAP1 ENSG00000104381 8:74321130-74488872 
Homo sapiens PI15 ENSG00000137558 8:74824534-74855029 
Mus musculus ELOC ENSMUSG00000079658 1:16641725-16657042 
Mus musculus TMEM70 ENSMUSG00000025940 1:16665207-16678275 
Mus musculus LY96 ENSMUSG00000025779 1:16688051-16709611 
Mus musculus JPH1 ENSMUSG00000042686 1:16964560-17097889 
Mus musculus GDAP1 ENSMUSG00000025777 1:17145362-17164271 
Mus musculus PI15 ENSMUSG00000067780 1:17601901-17630939 
Gallus gallus ELOC ENSGALG00000035417 2:118445078-118458839 
Gallus gallus TMEM70 ENSGALG00000033568 2:118458980-118463535 
Gallus gallus LY96 ENSGALG00000032701 2:118468953-118475495 
Gallus gallus JPH1 ENSGALG00000035845 2:118543324-118621765 
Gallus gallus GDAP1 ENSGALG00000042798 2:118637735-118644214 
Gallus gallus PI15 ENSGALG00000029264 2:118812721-118835079 
Danio rerio ELOCb ENSDARG00000045359 2:30244376-30250311 
Danio rerio TMEM70 ENSDARG00000078773 2:30249977-30252347 
Danio rerio LY96 ENSDARG00000105462 2:30281444-30286249 
Danio rerio JPH1b ENSDARG00000038826 2:30290719-30324610 





Table AA2: Genome locations for TLR4 proteins shown for synteny analysis. 
Genomic locations were obtained from Ensembl database.  
 
Species Protein Accession Chromosome Location 
Homo sapiens ASTN2 ENSG00000148219 9:116425225-117415070 
Homo sapiens TRIM32 ENSG00000119401 9:116687302-116701300 
Homo sapiens TLR4 ENSG00000136869 9:117704175-117724730 
Homo sapiens BRINP1 ENSG00000078725 9:119153458-119369467 
Homo sapiens CDK5RAP ENSG00000136861 9:120388869-120580170 
Mus musculus ASTN2 ENSMUSG00000028373 4:65380803-66404611 
Mus musculus TRIM32 ENSMUSG00000051675 4:65604986-65616238 
Mus musculus TLR4 ENSMUSG00000039005 4:66827584-66930284 
Mus musculus BRINP1 ENSMUSG00000028351 4:68761514-68954397 
Mus musculus CDK5RAP ENSMUSG00000039298 4:70216856-70410443 
Gallus gallus ASTN2 ENSGALG00000007038 17:3724742-3998741 
Gallus gallus TRIM32 ENSGALG00000034426 17:3818049-3819992 
Gallus gallus TLR4 ENSGALG00000007001 17:4083114-4088567 
Gallus gallus BRINP1 ENSGALG00000006997 17:4502517-4580960 
Gallus gallus CDK5RAP ENSGALG00000041102 17:5006022-5105974 
Xenopus 








tropocalis TLR4 NA GL172772:2026416- 2028407 
Xenopus 
tropocalis BRINP1 ENSXETG00000000244 
GL172772.1: 2,180,027-
2,198,495 
Danio rerio TLR4ba ENSDARG00000019742 13:18514788-18517453 
Danio rerio TLR4a1 ENSDARG00000075671 13:18520738-18523378 
Danio rerio TLR4bb ENSDARG00000022048 13:18523661-18528862 
Lepisosteus 
oculatus TLR4 ENSLOCG00000003751 LG21:5778346-5781017 
Lepisosteus 







SUPPLEMENTAL MATERIAL FOR CHAPTER III 
 
This section includes the figures and tables referenced in Chapter II. The experimental 
work was completed by me. J.T. Bridgham contributed technical expertise. This excerpt 
was written by me with editorial assistance by M.J. Harms. This work was published as 
part of Loes, A.N., J.T. Bridgham, M.J. Harms. 2018. “Coevolution of the Toll-like 





Table AB1. Genome locations for proteins shown for synteny analysis in human, 
mouse, opossum, duck and chicken. Genomic locations obtained from Ensembl 
database. 
 
Organism ID Protein Genomic Location 
Homo sapiens ENSG00000163220 S100A9 1:153357854-153361027 
Homo sapiens ENSG00000163221 S100A12 1:153373706-153375649 
Homo sapiens ENSG00000143546 S100A8 1:153390032-153391188 
Homo sapiens ENSG00000184330 S100A7A 1:153416524-153423225 
Homo sapiens ENSG00000197364 
S100A7L
2 1:153437058-153439949 
Homo sapiens ENSG00000143556 S100A7 1:153457744-153460701 
Homo sapiens ENSG00000197956 S100A6 1:153534599-153536244 
Homo sapiens ENSG00000196420 S100A5 1:153537147-153541765 
Homo sapiens ENSG00000196154 S100A4 1:153543613-153550136 
Mus musculus ENSMUSG00000056071 S100A9 3:90692632-90695721 
Mus musculus ENSMUSG00000056054 S100A8 3:90668978-90670035 
Mus musculus ENSMUSG00000001025 S100A6 3:90612882-90624181 
Mus musculus ENSMUSG00000001023 S100A5 3:90608523-90611780 
Mus musculus ENSMUSG00000001020 S100A4 3:90603771-90606045 
Monodelphis 
domestica ENSMODG00000017406 S100A9 2:187687578-187692267 
Monodelphis 
domestica ENSMODG00000017410 S100A12 2:187668840-187671749 
Monodelphis 
domestica ENSMODG00000017403 S100A8 2:187727543-187728740 
Monodelphis 
domestica ENSMODG00000017402 S100A7 2:187744792-187750533 
Monodelphis 
domestica ENSMODG00000017400 S100A6 2:187846539-187848831 
Monodelphis 
domestica ENSMODG00000017397 S100A4 2:187864578-187865727 
Gallus gallus ENSGALG00000024272 S100A8 25:1885186-1886619 
Gallus gallus ENSGALG00000041826 S100A6 25:1874283-1875569 
Gallus gallus ENSGALG00000037599 S100A4 25:1868937-1871234 
Anas platyrhynchos ENSAPLG00000010189 MRP-126 
KB742558.1: 42667-
47205 
Anas platyrhynchos Unannotated S100A7 KB742558: 39193-39333 
Anas platyrhynchos ENSAPLG00000010172 S100A6 
KB742558.1: 32550-
33337 








Figure AB1. Alternative phylogenies for a subset of the S100 family are consistent 
with MRP-126 designation as a calgranulin a) Bayesian phylogeny of 172 sequences 
and b) Maximum-likelihood phylogeny of 445 sequences for proteins within a subclade 
of the S100 family. C-terminal tails of sequences were truncated prior to resolving the 
phylogeny. Wedges are collapsed clades of orthologs, with wedge height corresponding 
to the number of included taxa and wedge length indicating the longest branch length 
with the clade. Support values are SH-supports calculated using an approximate 
likelihood ratio test. Clades are colored to highlight calgranulins (red) or S100A7/A15 
(orange). The taxa included in each clade are noted on the tree. * indicates marsupial 





Figure AB2. Dose-response of calgranulins against alternate species 
TLR4/MD2/CD14 complexes NF-κB activity for calgranulins from human ( ), mouse 
( ), opossum ( ), and chicken ( ) against TLR4/MD2/CD14 complexes from a) human, 
b) mouse, c) opossum and d) chicken. LPS was used as a positive control for expression 
and activation of the complex. Polymixin B is included to control for endotoxin-mediated 
activation of the complex. Activity is normalized to LPS activity of positive control 
within each biological replicate. Points are biological triplicates. Error bars for line plots 








Figure AB3. Complementation of TLR4 cofactors: human vs. mouse. Activation of 
human and mouse TLR4 in the presence of human and mouse MD-2 and CD14 by both 
LPS and calgranulins. Transfection conditions are noted above each panel (i.e. mouse 
CD14 is shown as mCD14, and human CD14 is hCD14, respectively). NF-κB is 
normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 









Figure AB4. Complementation of TLR4 cofactors: human vs. opossum. Activation of 
human and opossum TLR4 in the presence of human and opossum MD-2 and CD14 by 
both LPS and calgranulins. Transfection conditions are noted above each panel. NF-κB is 
normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 







Figure AB5. Complementation of TLR4 cofactors: human vs. chicken. Activation of 
human and chicken TLR4 in the presence of human and chicken MD-2 and CD14 by 
both LPS and calgranulins. Transfection conditions are noted above each panel. NF-κB is 
normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 






Figure AB6. Complementation of TLR4 cofactors: mouse vs. opossum. Activation of 
mouse and opossum TLR4 in the presence of mouse and opossum MD-2 and CD14 by 
both LPS and calgranulins. Transfection conditions are noted above each panel. NF-κB is 
normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 







Figure AB7. Complementation of TLR4 cofactors: mouse vs. chicken. Activation of 
mouse and chicken TLR4 in the presence of mouse and chicken MD-2 and CD14 by both 
LPS and calgranulins. Transfection conditions are noted above each panel. NF-κB is 
normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 






Figure AB8. Complementation of TLR4 cofactors: opossum vs. chicken. Activation 
of opossum and chicken TLR4 in the presence of opossum and chicken MD-2 and CD14 
by both LPS and calgranulins. Transfection conditions are noted above each panel. NF-
κB is normalized to LPS activation of the control complex for that species. Points are the 
technical triplicates from three biological replicates; error bars show standard error with 
mean shown as a bold line. Colors show treatment conditions: Buffer + PB (grey), LPS 







Figure AB9. Activation of TLR4 by recombinant proteins in the presence and 
absence of polymixin B. NF-κB activity for TLR4/MD2/CD14 complexes from 
amniotes treated with LPS (100 ng/mL), or 2 uM recombinant protein in phosphate 
buffered saline with and without 50 ug/mL or 100 ug/mL Polymixin B (PB). The ratio of 
Firefly luciferase to Renilla luciferase is shown. Points are technical triplicates from a 
single biological replicate. Bold line shows mean of technical replicates. Error bars are 






Figure AB10. Constitutive activity of TLR4 complexes from different species NF-κB 
activity for TLR4/MD2/CD14 complexes from amniotes treated with phosphate buffered 
saline (PBS) with and without LPS (100 ng/mL). Polymixin B (50 ug/mL) was included 
in buffer samples to control for endotoxin-mediated activation of the complex. A “+” in 
the table below each series indicates which components are included in that treatment. 
The ratio of Firefly luciferase to Renilla luciferase is shown. Points are the technical 
replicates from three biological replicates; error bars show standard error with mean 











SUPPLEMENTAL MATERIAL FOR CHAPTER IV 
 
This section includes the figures and tables referenced in Chapter IV. This section 
contains co-authored material. The experimental work was completed by me and Ran Shi 
with supervised by me and M.J. Harms. This chapter was written by me with editorial 





Table AC1. Amino acid sequences for proteins used in this study. Wildtype protein 
sequence for human S100A9 was obtained from UniProt. Mutagenesis was performed 






















Table AC2. S100A9 depletes metals from cell culture media. Metal concentrations 
identified with ICP-MS in DMEM and in DMEM + 10% FBS treated with 2 uM protein.  
 
Sample Rep Ca [mM] Mn [nM] Fe [nM] Cu [nM] Zn [nM] 
S100A9(WT) 1 1.122547 <20 <56 39.90628 405.7573 
S100(Δ99) 1 1.128009 <20 <56 41.25464 465.7686 
S100A9(C3S) 1 1.038788 <20 <56 39.8894 320.2949 
S100A9(ΔZn) 1 1.103102 <20 <56 44.2999 705.4366 
DMEM+FBS 1 1.12145 <20 <56 39.64886 716.2602 
DMEM 1 1.053144 <20 <56 16.99926 <104 
S100A9(WT) 2 1.076186 <20 <56 33.46436 407.3709 
S100(Δ99) 2 1.103707 <20 <56 40.11286 497.2861 
S100A9(C3S) 2 1.104335 <20 <56 39.28092 370.9397 
S100A9(ΔZn) 2 1.08796 <20 <56 33.82844 736.1877 
DMEM+FBS 2 1.063412 <20 <56 53.21472 761.2194 
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Figure AD1. Phylogeny for calgranulin tree with highest log-likelihood. Fifteen 
possible topologies for the calgranulin clade were used in reconstructions. This topology 
which had the highest log-likelihood was used for ancestral state reconstruction. Support 





Figure AD2. Species corrected phylogeny of TLR4. A maximum likelihood phylogeny 
of TLR4 was solved using the JTT model and manually species-corrected. Genus and 
species are shown for tip labels. Colors are used to show clades of fish (blue), amphibians 
(green), birds and reptiles (orange), and mammals (purple). Support values are SH-





Figure AD3. Species corrected phylogeny for MD-2. A maximum likelihood 
phylogeny of MD-2 was solved using the JTT model and manually species-corrected. 
Genus and species are shown for tip labels. Colors are used to show clades of fish (blue), 
amphibians (green), birds and reptiles (orange), and mammals (purple). Support values 





Figure AD4. Species-corrected phylogeny for CD14. A maximum likelihood 
phylogeny of TLR4 was solved using the JTT model and manually species-corrected. 
Genus and species are shown for tip labels. Colors are used to show clades of fish (blue), 
amphibians (green), birds and reptiles (orange), and mammals (purple). Support values 
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